FI934422L - Bibliotek av heterodimera receptorer med anvaendning av fagemider - Google Patents

Bibliotek av heterodimera receptorer med anvaendning av fagemider Download PDF

Info

Publication number: FI934422L
Authority: FI; Finland
Prior art keywords: receptorer; heterodimera; fagemider; bibliotek; anvaendning
Prior art date: 1991-04-10

Application number

FI934422A

Other languages

English (en)

Other versions

FI120309B (fi

FI934422A0 (fi

Inventor

Angray Kang

Carlos Barbas

Richard A Lerner

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-10

Filing date

1993-10-08

Publication date

1993-12-08

1993-10-08 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

1993-10-08 Publication of FI934422A0 publication Critical patent/FI934422A0/fi

1993-12-08 Publication of FI934422L publication Critical patent/FI934422L/fi

2009-09-15 Application granted granted Critical

2009-09-15 Publication of FI120309B publication Critical patent/FI120309B/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Virology (AREA)
Crystallography & Structural Chemistry (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

FI934422A 1991-04-10 1993-10-08 Heterodimeerisiä reseptorikirjastoja, jotka käyttävät fagomideja FI120309B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US68360291A	1991-04-10	1991-04-10
US68360291		1991-04-10
US82662392A	1992-01-27	1992-01-27
US82662392		1992-01-27
PCT/US1992/003091 WO1992018619A1 (en)	1991-04-10	1992-04-10	Heterodimeric receptor libraries using phagemids
US9203091		1992-04-10

Publications (3)

Publication Number	Publication Date
FI934422A0 FI934422A0 (fi)	1993-10-08
FI934422L true FI934422L (fi)	1993-12-08
FI120309B FI120309B (fi)	2009-09-15

Family

ID=27103149

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI934422A FI120309B (fi)	1991-04-10	1993-10-08	Heterodimeerisiä reseptorikirjastoja, jotka käyttävät fagomideja

Country Status (14)

Country	Link
US (6)	US5658727A (fi)
EP (2)	EP1471142B1 (fi)
JP (4)	JP3672306B2 (fi)
AT (2)	ATE269401T1 (fi)
AU (1)	AU662148B2 (fi)
CA (1)	CA2108147C (fi)
DE (2)	DE69233750D1 (fi)
DK (2)	DK1471142T3 (fi)
ES (2)	ES2315612T3 (fi)
FI (1)	FI120309B (fi)
IE (1)	IE921169A1 (fi)
NO (1)	NO319371B1 (fi)
PT (1)	PT100379B (fi)
WO (1)	WO1992018619A1 (fi)

Families Citing this family (1328)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US7063943B1 (en)	1990-07-10	2006-06-20	Cambridge Antibody Technology	Methods for producing members of specific binding pairs
GB9206318D0 (en) *	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
US6916605B1 (en)	1990-07-10	2005-07-12	Medical Research Council	Methods for producing members of specific binding pairs
DE69129154T2 (de) *	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE269401T1 (de) *	1991-04-10	2004-07-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US5962255A (en) *	1992-03-24	1999-10-05	Cambridge Antibody Technology Limited	Methods for producing recombinant vectors
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
US5858657A (en) *	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
US6492160B1 (en)	1991-05-15	2002-12-10	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5733731A (en) *	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
US5270170A (en) *	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US7067284B1 (en) *	1992-01-27	2006-06-27	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5733743A (en) *	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US6214613B1 (en)	1993-12-03	2001-04-10	Ashai Kasei Kogyo Kabushiki Kaisha	Expression screening vector
US20060078561A1 (en) *	1994-01-31	2006-04-13	The Trustees Of Boston University	Polyclonal antibody libraries
PT1231268E (pt) *	1994-01-31	2005-11-30	Univ Boston	Bancos de anticorpos policlonais
US6576236B1 (en)	1994-07-01	2003-06-10	Dana Farber Cancer Institute	Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US7597886B2 (en) *	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7820798B2 (en) *	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US6326155B1 (en) *	1995-03-20	2001-12-04	Dyax Corp.	Engineering affinity ligands for macromolecules
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US5702892A (en) *	1995-05-09	1997-12-30	The United States Of America As Represented By The Department Of Health And Human Services	Phage-display of immunoglobulin heavy chain libraries
US6475806B1 (en) *	1995-06-07	2002-11-05	Praecis Pharmaceuticals, Inc.	Anchor libraries and identification of peptide binding sequences
US7368111B2 (en)	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US5830696A (en)	1996-12-05	1998-11-03	Diversa Corporation	Directed evolution of thermophilic enzymes
US6939689B2 (en)	1995-12-07	2005-09-06	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US6713279B1 (en)	1995-12-07	2004-03-30	Diversa Corporation	Non-stochastic generation of genetic vaccines and enzymes
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US6764835B2 (en)	1995-12-07	2004-07-20	Diversa Corporation	Saturation mutageneis in directed evolution
US6740506B2 (en)	1995-12-07	2004-05-25	Diversa Corporation	End selection in directed evolution
US20030219752A1 (en) *	1995-12-07	2003-11-27	Diversa Corporation	Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6358709B1 (en)	1995-12-07	2002-03-19	Diversa Corporation	End selection in directed evolution
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
DE19629143A1 (de) *	1996-07-19	1998-01-22	Bayer Ag	Vorrichtung zum Separieren von Mikroobjekten
US5985543A (en)	1996-10-11	1999-11-16	The Trustees Of The University Of Pennsylvania	Compositions and methods for detection of antibody binding to cells
US5876925A (en) *	1996-10-11	1999-03-02	The Trustees Of The University Of Pennsylvania	Magnetically activated cell sorting for production of proteins
IL119587A (en) *	1996-11-07	2000-12-06	Univ Ramot	Method of preparing and for obtaining bimolecular interactions
US5817497A (en) *	1996-11-26	1998-10-06	Incyte Pharmaceuticals	Glutathione s-transferase
EP0977886A4 (en) *	1997-03-07	2002-10-23	Sunol Molecular Corp	FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
US6555310B1 (en) *	1997-04-04	2003-04-29	Biosite Diagnostics, Inc.	Polyclonal libraries
WO1998047343A2 (en) *	1997-04-04	1998-10-29	Biosite Diagnostics, Inc.	Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
US6057098A (en)	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
NZ500078A (en)	1997-04-07	2001-10-26	Genentech Inc	Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
ATE501170T1 (de) *	1997-04-07	2011-03-15	Genentech Inc	Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
DE69837085T3 (de)	1997-04-16	2012-01-12	Millennium Pharmaceuticals, Inc.	Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
NZ516848A (en)	1997-06-20	2004-03-26	Ciphergen Biosystems Inc	Retentate chromatography apparatus with applications in biology and medicine
ES2334184T3 (es) *	1997-11-17	2010-03-05	Micromet Ag	Metodo de identificacion de dominios de sitios de union que conservan la capacidad de unirse a un epitopo.
WO1999031265A1 (en)	1997-12-12	1999-06-24	Way Jeffrey C	Compounds and methods for the inhibition of protein-protein interactions
US7390619B1 (en)	1998-02-11	2008-06-24	Maxygen, Inc.	Optimization of immunomodulatory properties of genetic vaccines
EP1093457B8 (en)	1998-03-19	2011-02-02	Human Genome Sciences, Inc.	Cytokine receptor common gamma chain like
US6344330B1 (en)	1998-03-27	2002-02-05	The Regents Of The University Of California	Pharmacophore recombination for the identification of small molecule drug lead compounds
US7056517B2 (en)	1998-04-13	2006-06-06	The Forsyth Institute	Glucosyltransferase immunogens
US7163682B2 (en)	1998-04-13	2007-01-16	The Forsyth Institute	Glucan binding protein and glucosyltransferase immunogens
EP2311490A3 (en)	1998-07-13	2011-05-04	Board of Regents, The University of Texas System	Uses of antibodies to aminophospholipids for cancer treatment
EP1100890A2 (en)	1998-07-27	2001-05-23	Genentech, Inc.	Improved transformation efficiency in phage display through modification of a coat protein
US6190908B1 (en) *	1998-08-12	2001-02-20	The Scripps Research Institute	Modulation of polypeptide display on modified filamentous phage
US6420110B1 (en)	1998-10-19	2002-07-16	Gpc Biotech, Inc.	Methods and reagents for isolating biologically active peptides
IL127127A0 (en) *	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
US20090130718A1 (en) *	1999-02-04	2009-05-21	Diversa Corporation	Gene site saturation mutagenesis
WO2000050620A2 (en)	1999-02-26	2000-08-31	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
EP2301947A3 (en)	1999-02-26	2011-11-23	Millennium Pharmaceuticals, Inc.	Secreted proteins and uses thereof
WO2001077137A1 (en)	2000-04-12	2001-10-18	Human Genome Sciences, Inc.	Albumin fusion proteins
DK2168984T3 (da)	1999-03-25	2012-12-10	Abbott Gmbh & Co Kg	Humane antistoffer, som binder humant IL-12, og fremgangsmåder til pro-duktion heraf
DE19915057A1 (de)	1999-04-01	2000-10-19	Forschungszentrum Borstel	Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
US20020102613A1 (en)	1999-05-18	2002-08-01	Hoogenboom Hendricus Renerus Jacobus Mattheus	Novel Fab fragment libraries and methods for their use
PT2067788E (pt) *	1999-05-18	2015-10-29	Dyax Corp	Bibliotecas de fragmentos fab e métodos para a sua utilização
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US20040001826A1 (en) *	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US6808710B1 (en)	1999-08-23	2004-10-26	Genetics Institute, Inc.	Downmodulating an immune response with multivalent antibodies to PD-1
US6673346B1 (en) *	1999-08-31	2004-01-06	The Regents Of The University Of Michigan	Compositions and methods for the treatment of sepsis
US20070111259A1 (en) *	1999-10-02	2007-05-17	Medarex, Inc.	Human antibodies
US6794132B2 (en)	1999-10-02	2004-09-21	Biosite, Inc.	Human antibodies
US7135287B1 (en)	1999-10-02	2006-11-14	Biosite, Inc.	Human antibodies
US6680209B1 (en)	1999-12-06	2004-01-20	Biosite, Incorporated	Human antibodies as diagnostic reagents
AU784983B2 (en) *	1999-12-15	2006-08-17	Genentech Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003518942A (ja)	1999-12-30	2003-06-17	プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ	肝細胞成長、形質細胞分化、又はｔ細胞サブセットの活性を、ｘｂｐ−１活性の変調により変調することに関する方法及び組成物
IL151044A0 (en)	2000-02-10	2003-04-10	Abbott Lab	Antibodies that bind human interleukin-18 and methods of making and using
EP2341075A1 (en) *	2000-03-01	2011-07-06	MedImmune, LLC	Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US20040029113A1 (en) *	2000-04-17	2004-02-12	Ladner Robert C.	Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7495070B2 (en) *	2000-04-24	2009-02-24	Yale University	Protein binding miniature proteins
EP1309680B1 (en) *	2000-04-24	2006-04-19	Yale University	Dna & protein binding miniature proteins
EP1714661A3 (en)	2000-05-19	2012-03-14	The Center for Blood Research, INC.	Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001275378A1 (en)	2000-06-08	2001-12-17	The Center For Blood Research, Inc.	Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
EP2431054A3 (en)	2000-06-15	2013-03-06	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
KR20060088905A (ko)	2000-06-16	2006-08-07	휴먼 게놈 사이언시즈, 인코포레이티드	면역특이적으로 ＢＬｙＳ에 결합하는 항체
AU2001273096B8 (en)	2000-06-28	2005-10-13	Dana-Farber Cancer Institute, Inc.	PD-L2 molecules: novel PD-1 ligands and uses therefor
DE60143986D1 (de)	2000-07-14	2011-03-17	Cropdesign Nv	Inhibitoren für cyclin-dependent-kinase von pflanzen
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
GB0022978D0 (en)	2000-09-19	2000-11-01	Oxford Glycosciences Uk Ltd	Detection of peptides
US7405276B2 (en)	2000-11-01	2008-07-29	Elusys Therapeutics, Inc.	Method of producing bispecific molecules by protein trans-splicing
EP1343912A2 (en)	2000-11-28	2003-09-17	Wyeth	Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JP2004526425A (ja)	2000-11-28	2004-09-02	ワイス	前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
TWI327600B (en)	2000-11-28	2010-07-21	Medimmune Llc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002046434A2 (en) *	2000-12-08	2002-06-13	Alexion Pharmaceuticals, Inc.	Plasmid vectors
EP1355919B1 (en)	2000-12-12	2010-11-24	MedImmune, LLC	Molecules with extended half-lives, compositions and uses thereof
US6979556B2 (en) *	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
PT2316940E (pt)	2000-12-18	2013-10-16	Dyax Corp	Bibliotecas orientadas de pacotes genéticos
JP4986370B2 (ja)	2000-12-22	2012-07-25	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	Ｒｇｍおよびそのモジュレーターの用途
CN100357278C (zh) *	2000-12-22	2007-12-26	奥索-麦克尼尔药品公司	作为激酶抑制剂的取代的三唑二胺衍生物
SV2007000775A (es)	2001-01-05	2007-03-15	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
CA2437811A1 (en)	2001-02-09	2002-08-22	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
EP2316276A3 (en)	2001-02-23	2011-08-03	DSM IP Assets B.V.	Genes encoding proteolytic enzymes from aspargilli
US20030165873A1 (en)	2001-03-02	2003-09-04	Come Jon H.	Three hybrid assay system
WO2002069904A2 (en) *	2001-03-02	2002-09-12	Medimmune, Inc.	Cd2 antagonists for treatment of autoimmune or inflammatory disease
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en)	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) *	2001-03-20	2009-03-26	Bioxell S.P.A.	Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) *	2001-03-20	2013-11-12	Marco Colonna	A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
EP2294917A1 (en)	2001-03-22	2011-03-16	Abbott GmbH & Co. KG	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
WO2002079499A1 (en)	2001-04-02	2002-10-10	Wyeth	Pd-1, a receptor for b7-4, and uses therefor
DK1385864T3 (da)	2001-04-13	2010-08-16	Human Genome Sciences Inc	Anti-VEGF-2-antistoffer
CN1636062A (zh)	2001-04-16	2005-07-06	惠氏控股公司	编码多肽抗原的新肺炎链球菌可读框及其应用
ES2255616T3 (es) *	2001-04-27	2006-07-01	Alexion Pharmaceuticals, Inc.	Vectores fagemidos.
US7064189B2 (en)	2001-05-25	2006-06-20	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
US20060239533A1 (en) *	2001-06-04	2006-10-26	Triantafyllos Tafas	Method for detecting infectious agents using computer controlled automated image analysis
CA2385745C (en)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US20030124144A1 (en) *	2001-06-21	2003-07-03	Larry Cosenza	Chimeric capsid proteins and uses thereof
US20040002058A1 (en) *	2001-06-21	2004-01-01	Uab Research Foundation	Chimeric capsid proteins and uses thereof
EP2270184A3 (en)	2001-06-22	2012-04-11	Pioneer Hi-Bred International, Inc.	Defensin polynucleotides and methods of use
CA2450236A1 (en) *	2001-07-06	2003-01-16	Genentech, Inc.	Phage displayed pdz domain ligands
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
MXPA04001566A (es) *	2001-08-27	2004-05-17	Genentech Inc	Un sistema para expresion y ensamblado de anticuerpos.
US20040142325A1 (en)	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
JP4360906B2 (ja) *	2001-09-14	2009-11-11	サイトスバイオテクノロジーアーゲー	ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003025202A2 (en) *	2001-09-19	2003-03-27	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
US7414111B2 (en) *	2001-09-19	2008-08-19	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
DE60232672D1 (de) *	2001-10-01	2009-07-30	Dyax Corp	Mehrkettige eukaryontische display-vektoren und deren verwendungen
US20040005709A1 (en) *	2001-10-24	2004-01-08	Hoogenboom Henricus Renerus Jacobus Mattheus	Hybridization control of sequence variation
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
KR100450864B1 (ko) *	2001-11-23	2004-10-01	한국과학기술연구원	Ｒｎａ 표적 분자에 대해 특이성이 향상된네오마이신-클로람페니콜 헤테로 이합체 및 그의 제조방법
US7858297B2 (en)	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
JP2005527191A (ja)	2001-12-18	2005-09-15	アンドキューブソシエタパーアクシオンシンプリフィー	新規の細胞死関連タンパク質ならびにアポトーシス制御におけるｔｈａｐ１およびｐａｒ４の経路
EP1463807A4 (en)	2001-12-19	2006-04-12	Bristol Myers Squibb Co	FORMATHYDROGENASE FROM PICHIA PASTORIS AND USES THEREOF
EP2277889B1 (en)	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
US20040009498A1 (en) *	2002-01-14	2004-01-15	Diversa Corporation	Chimeric antigen binding molecules and methods for making and using them
US20070166704A1 (en) *	2002-01-18	2007-07-19	Fei Huang	Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways
US7094579B2 (en)	2002-02-13	2006-08-22	Xoma Technology Ltd.	Eukaryotic signal sequences for prokaryotic expression
WO2003072054A2 (en) *	2002-02-25	2003-09-04	Cabot Corporation	Custom ligand design for biomolecular filtration and purification for bioseperation
WO2003073910A2 (en) *	2002-03-01	2003-09-12	Bayer Corporation	Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
WO2003073909A2 (en)	2002-03-01	2003-09-12	Bayer Corporation	Assays to monitor levels of epidermal growth factor receptor (egfr) extracellular domain (ecd) in cancer patients
JP2005531511A (ja)	2002-03-07	2005-10-20	ザフォーシスインスティチュート	グルカン結合タンパク質の免疫原性
WO2003085093A2 (en) *	2002-04-01	2003-10-16	Human Genome Sciences, Inc.	Antibodies that specifically bind to gmad
GB0207533D0 (en)	2002-04-02	2002-05-08	Oxford Glycosciences Uk Ltd	Protein
US7745192B2 (en)	2002-04-03	2010-06-29	Venomics Pty Limited	Prothrombin activating protein
US7371383B2 (en)	2002-04-12	2008-05-13	Medimmune, Inc.	Recombinant anti-interleukin-9 antibodies
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
DE60333629D1 (de)	2002-05-21	2010-09-16	Dsm Ip Assets Bv	Neue phospholipasen und deren verwendungen
CA2488441C (en) *	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
EP2305710A3 (en)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetic antibody phage libraries
EP1531848A4 (en) *	2002-06-10	2007-03-28	Vaccinex Inc	DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2489595C (en) *	2002-06-14	2013-05-28	Simon E. Hufton	Recombination of nucleic acid library members
EP2283868B1 (en)	2002-07-15	2016-03-30	Board of Regents, The University of Texas System	Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
CA2872136C (en)	2002-07-18	2017-06-20	Merus B.V.	Recombinant production of mixtures of antibodies
BR0312785A (pt)	2002-07-19	2005-08-30	Abbott Biotech Ltd	Tratamento de desordens relacionadas a tnf(alfa)
US7250551B2 (en)	2002-07-24	2007-07-31	President And Fellows Of Harvard College	Transgenic mice expressing inducible human p25
KR20050062525A (ko)	2002-08-10	2005-06-23	예일 유니버시티	Ｎｏｇｏ 수용체 길항제
US20040067532A1 (en) *	2002-08-12	2004-04-08	Genetastix Corporation	High throughput generation and affinity maturation of humanized antibody
ES2381617T5 (es)	2002-08-14	2016-02-24	Macrogenics, Inc.	Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
PL375355A1 (en)	2002-08-19	2005-11-28	Dsm Ip Assets B.V.	Novel lipases and uses thereof
AU2003250518A1 (en)	2002-08-20	2004-03-11	Yeda Research And Development Co. Ltd.	Akap84 and its use for visualization of biological structures
ATE519862T1 (de)	2002-08-20	2011-08-15	Millennium Pharm Inc	Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
AU2003295326A1 (en)	2002-09-04	2004-04-23		Cancer therapy using beta glucan and antibodies
JP4596916B2 (ja) *	2002-09-05	2010-12-15	メディミューン，エルエルシー	Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
MXPA05002934A (es) *	2002-09-18	2006-02-24	Univ Pennsylvania	Composiciones, metodos y kits para deteccion de un antigeno en una celula y en una mezcla biologica.
DK2891666T3 (en)	2002-10-16	2017-10-02	Purdue Pharma Lp	Antibodies that bind cell-associated CA 125 / O722P and methods for its use
US7427469B2 (en) *	2002-11-05	2008-09-23	Institut Pasteur	Method of treating cytomegalovirus with DC-SIGN blockers
AU2003301804A1 (en) *	2002-11-05	2004-06-07	Institut National De La Sante Et De La Recherche Medicale	Dc-sign blockers and their use for preventing or treating viral infections.
EP1629090B1 (en) *	2002-11-06	2014-03-05	iBio, Inc.	Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) *	2002-11-12	2010-04-06	Ibio, Inc.	Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) *	2002-11-12	2010-03-23	iBio, Inc. and Fraunhofer USA, Inc.	Production of pharmaceutically active proteins in sprouted seedlings
US20040180422A1 (en) *	2002-11-26	2004-09-16	Dyax Corp.	Methods and compositions for controlling valency of phage display
DE10256669B4 (de) *	2002-12-04	2006-03-09	Universitätsklinikum Charité an der Humboldt-Universität zu Berlin Technologietransferstelle	Gemisch mindestens zweier Fusionsproteine sowie ihre Herstellung und Verwendung
ES2362424T3 (es) *	2003-01-07	2011-07-05	Dyax Corporation	Biblioteca del dominio kunitz.
EP1585767A2 (en) *	2003-01-16	2005-10-19	Genentech, Inc.	Synthetic antibody phage libraries
AU2004206250B8 (en)	2003-01-21	2009-09-17	Bristol-Myers Squibb Company	Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004209660A1 (en)	2003-02-03	2004-08-19	Fraunhofer Usa, Inc.	System for expression of genes in plants
EP1947116B1 (en)	2003-02-10	2017-06-21	2-BBB Medicines B.V.	Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
CA2516455C (en)	2003-02-20	2012-05-01	Seattle Genetics, Inc.	Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20040180387A1 (en)	2003-03-13	2004-09-16	Fujirebio Diagnostics, Inc.	Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
EA010055B1 (ru)	2003-03-19	2008-06-30	Байоджен Айдек Ма Инк.	ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
US7294701B2 (en) *	2003-04-02	2007-11-13	Technion Research & Development Foundation Ltd.	Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
WO2004091510A2 (en)	2003-04-11	2004-10-28	Medimmune, Inc.	Recombinant il-9 antibodies and uses thereof
US20050014932A1 (en)	2003-05-15	2005-01-20	Iogenetics, Llc	Targeted biocides
ES2427641T3 (es)	2003-05-22	2013-10-31	Ibio, Inc.	Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
AU2004242614B2 (en)	2003-05-30	2011-09-22	Merus N.V.	Fab library for the preparation of anti vegf and anti rabies virus fabs
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
CA2542232A1 (en)	2003-06-09	2005-01-20	Alnylam Pharmaceuticals, Inc.	Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US20050058658A1 (en) *	2003-07-15	2005-03-17	Barros Research Institute	Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
AU2004259727A1 (en) *	2003-07-15	2005-02-03	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases.
WO2005011580A2 (en) *	2003-07-25	2005-02-10	Board Of Regents, The University Of Texas System	Compositions and methods for herpes simplex prophylaxis and treatment
US7619059B2 (en)	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
CA2445420A1 (en)	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
KR20060069825A (ko) *	2003-08-01	2006-06-22	제넨테크, 인크.	제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
US20050106667A1 (en) *	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
EP2128270B1 (en)	2003-08-08	2012-10-03	Genenews Inc.	Osteoarthritis biomarkers and uses thereof
WO2005042743A2 (en)	2003-08-18	2005-05-12	Medimmune, Inc.	Humanization of antibodies
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
EP2051077A3 (en)	2003-10-07	2009-05-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
IL158287A0 (en)	2003-10-07	2004-05-12	Yeda Res & Dev	Antibodies to nik, their preparation and use
WO2005035569A2 (en) *	2003-10-10	2005-04-21	Five Prime Therapeutics, Inc.	Kiaa0779, splice variants thereof, and methods of their use
US7329725B1 (en) *	2003-10-29	2008-02-12	Nastech Pharmaceutical Company Inc.	Phage displayed Trp cage ligands
JP2005139011A (ja) *	2003-11-04	2005-06-02	Nof Corp	火薬原料及びその製造方法
GB0325836D0 (en) *	2003-11-05	2003-12-10	Celltech R&D Ltd	Biological products
US20050100965A1 (en)	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
CA2544920C (en) *	2003-11-21	2012-09-11	Celltech R & D Limited	Method for the treatment of multiple sclerosis by inhibiting il-17 activity
AU2004296184B2 (en) *	2003-12-04	2010-12-16	Vaccinex, Inc.	Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
GB0329825D0 (en) *	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
US20050266425A1 (en) *	2003-12-31	2005-12-01	Vaccinex, Inc.	Methods for producing and identifying multispecific antibodies
DE602005026779D1 (de)	2004-01-09	2011-04-21	Pfizer	ANTIKÖRPER GEGEN MAdCAM
ES2646560T3 (es)	2004-01-20	2017-12-14	Merus N.V.	Mezclas de proteínas de unión
WO2005072341A2 (en)	2004-01-21	2005-08-11	Fujirebio America, Inc.	Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
CA2554089C (en)	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005080432A2 (en)	2004-02-19	2005-09-01	Genentech, Inc.	Cdr-repaired antibodies
ES2532609T3 (es) *	2004-02-20	2015-03-30	Ibio, Inc.	Sistemas y métodos para expresión clonales en plantas
AU2005219839B9 (en)	2004-03-01	2011-12-22	Immune Disease Institute, Inc	Natural IgM antibodies and inhibitors thereof
KR20110027823A (ko)	2004-03-24	2011-03-16	트리패스 이미징, 인코포레이티드	자궁경부 질환의 검사 방법 및 조성물
WO2005097184A2 (en) *	2004-03-26	2005-10-20	Human Genome Sciences, Inc.	Antibodies against nogo receptor
TWI556829B (zh)	2004-04-09	2016-11-11	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7785903B2 (en) *	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
EP1745149A4 (en)	2004-04-15	2008-08-06	Univ Florida	NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
CA2562764A1 (en)	2004-04-23	2005-11-03	Richard Kroczek	Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US20060292554A1 (en) *	2004-05-18	2006-12-28	Genentech, Inc.	Major coat protein variants for C-terminal and bi-terminal display
EP2527447A1 (en)	2004-06-03	2012-11-28	Athlomics Pty Ltd	Agents and methods for diagnosing stress
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
WO2006002437A2 (en)	2004-06-24	2006-01-05	Biogen Idec Ma Inc.	Treatment of conditions involving demyelination
US7241598B2 (en) *	2004-06-29	2007-07-10	The Chinese University Of Hong Kong	Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
US6986264B1 (en) *	2004-07-15	2006-01-17	Carrier Corporation	Economized dehumidification system
CN101014365B (zh)	2004-07-16	2011-04-13	辉瑞产品公司	使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
US7342093B2 (en)	2004-07-23	2008-03-11	University Of Massachusetts	Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
CN101014245A (zh)	2004-08-03	2007-08-08	比奥根艾迪克Ma公司	神经元功能中的taj
CA2576195A1 (en) *	2004-08-05	2006-02-16	Biosite Incorporated	Compositions and methods for phage display of polypeptides
HUE028441T2 (hu) *	2004-09-03	2016-12-28	Genentech Inc	Humanizált anti-béta7 antagonisták és alkalmazásaik
CA2580921C (en)	2004-09-21	2016-04-12	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7435804B2 (en) *	2004-10-19	2008-10-14	Phage Biotechnology, Inc.	Method for obtaining single chain antibodies to human interferon α2b
WO2006047417A2 (en)	2004-10-21	2006-05-04	University Of Florida Research Foundation, Inc.	Detection of cannabinoid receptor biomarkers and uses thereof
EP1809326A4 (en)	2004-10-27	2009-11-04	Medimmune Inc	MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
AU2006204459B2 (en)	2005-01-05	2012-11-01	F-Star Therapeutics Limited	Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
CA2599589A1 (en)	2005-02-07	2006-08-17	Genenews,Inc.	Mild osteoarthritis biomarkers and uses thereof
KR101289537B1 (ko)	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
GB0503546D0 (en) *	2005-02-21	2005-03-30	Hellenic Pasteur Inst	Antibody
US20090142338A1 (en) *	2005-03-04	2009-06-04	Curedm, Inc.	Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US8211430B2 (en)	2005-03-04	2012-07-03	Curedm Group Holdings, Llc	Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
WO2006102095A2 (en)	2005-03-18	2006-09-28	Medimmune, Inc.	Framework-shuffling of antibodies
JP5225069B2 (ja)	2005-03-23	2013-07-03	ゲンマブエー／エス	多発性骨髄腫の治療のためのｃｄ３８に対する抗体
GB0506912D0 (en)	2005-04-05	2005-05-11	Celltech R&D Ltd	Biological products
WO2008157379A2 (en)	2007-06-21	2008-12-24	Macrogenics, Inc.	Covalent diabodies and uses thereof
WO2006113665A2 (en)	2005-04-15	2006-10-26	Macrogenics, Inc.	Covalent diabodies and uses thereof
US20060269556A1 (en) *	2005-04-18	2006-11-30	Karl Nocka	Mast cell activation using siglec 6 antibodies
EP2511299A1 (en)	2005-04-19	2012-10-17	Seattle Genetics, Inc.	Humanized anti-CD70 binding agents and uses thereof
ZA200709291B (en)	2005-04-25	2009-01-28	Pfizer	Antibodies to myostatin
EP2444421A1 (en)	2005-04-26	2012-04-25	Pfizer Inc.	P-Cadherin antibodies
US7595380B2 (en)	2005-04-27	2009-09-29	Tripath Imaging, Inc.	Monoclonal antibodies and methods for their use in the detection of cervical disease
EP1885755A4 (en)	2005-05-05	2009-07-29	Univ Duke	CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
MX2007014440A (es)	2005-05-16	2008-02-11	Abbott Biotech Ltd	Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
MX2007014474A (es)	2005-05-17	2008-02-07	Univ Connecticut	Composiciones y metodos para inmunomodulacion en un organismo.
EA013821B1 (ru)	2005-05-25	2010-08-30	Кьюрдм, Инк.	Проостровковые пептиды человека, их производные и аналоги и способы их применения
ES2605945T3 (es)	2005-05-27	2017-03-17	Biogen Ma Inc.	Anticuerpos de unión a Tweak
US7767789B2 (en) *	2005-06-02	2010-08-03	University Hopitals of Cleveland	Truncated proteins as cancer markers
NZ565044A (en)	2005-06-17	2010-05-28	Elan Pharma Int Ltd	Methods of purifying anti A beta antibodies with calcium chloride
US20070110757A1 (en)	2005-06-23	2007-05-17	Ziping Wei	Antibody formulations having optimized aggregation and fragmentation profiles
CN103146708A (zh) *	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
EP2476761A3 (en)	2005-07-07	2012-10-17	Athlomics Pty Ltd	Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
US7482124B2 (en) *	2005-07-08	2009-01-27	Bristol-Myers Squibb Company	Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
ES2434470T3 (es)	2005-07-08	2013-12-16	Biogen Idec Ma Inc.	Anticuerpos SP35 y usos de éstos
CA2617637C (en)	2005-08-02	2017-07-18	Xbiotech Inc.	Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
JP2009502180A (ja)	2005-08-03	2009-01-29	アデレイドリサーチアンドイノベーションピーティーワイリミテッド	多糖シンターゼ
CA2616859C (en) *	2005-08-03	2015-04-14	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
EP2500358A3 (en)	2005-08-19	2012-10-17	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20070202512A1 (en) *	2005-08-19	2007-08-30	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
MY169746A (en)	2005-08-19	2019-05-14	Abbvie Inc	Dual variable domain immunoglobulin and uses thereof
CN101517068B (zh)	2005-09-07	2017-02-08	安进弗里蒙特公司	活化素受体样激酶‑1的人单克隆抗体
AU2006290567A1 (en)	2005-09-14	2007-03-22	Ucb Pharma S.A	Comb polymers
CA2624562A1 (en)	2005-09-30	2007-04-12	Abbott Gmbh & Co. Kg	Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
GB0520169D0 (en) *	2005-10-04	2005-11-09	Celltech R&D Ltd	Biological products
US8249814B2 (en)	2005-10-21	2012-08-21	Genenews Inc.	Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
US8597646B2 (en)	2005-10-25	2013-12-03	The Johns Hopkins University	Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
EP2368868A1 (en)	2005-10-28	2011-09-28	Praecis Pharmaceuticals Inc.	Methods for identifying compounds of interest using encoded libraries
HRP20131112T1 (hr)	2005-11-01	2014-01-03	Abbvie Biotechnology Ltd	Postupak za odreä�ivanje uäśinkovitosti adalimumaba kod subjekata koji pate od ankilozantnog spondilitisa pomoä†u ctx-ii i mmp3 kao biomarkera
US20090246189A1 (en)	2005-11-04	2009-10-01	Biogen Idec Ma Inc. And Mclean Hospital	Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EA014900B1 (ru)	2005-11-07	2011-02-28	Зе Скрипс Ресеч Инститьют	Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
ATE547709T1 (de)	2005-11-14	2012-03-15	Metamol Theranostics Llc	Tumorinvasionsfördernde peptidsequenz
US20070122413A1 (en)	2005-11-28	2007-05-31	Sivakumar Pallavur V	Il-21 antagonists
JP5475994B2 (ja)	2005-11-30	2014-04-16	アッヴィ・インコーポレイテッド	抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101439828B1 (ko)	2005-11-30	2014-09-17	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CN103278647A (zh)	2005-11-30	2013-09-04	麻省理工学院	病原体检测生物传感器
KR101434682B1 (ko) *	2005-12-02	2014-08-27	제넨테크, 인크.	결합 폴리펩티드 및 이들의 용도
JP5312039B2 (ja)	2005-12-02	2013-10-09	バイオジェン・アイデック・エムエイ・インコーポレイテッド	脱髄の関与する状態の処置
US20070237764A1 (en) *	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
ZA200804594B (en) *	2005-12-09	2010-08-25	Ucb Pharma Sa	Antibody molecules having specificity for human IL-6
US20070264687A1 (en)	2005-12-15	2007-11-15	Min-Yuan Chou	Recombinant triplex scaffold-based polypeptides
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
US8014957B2 (en)	2005-12-15	2011-09-06	Fred Hutchinson Cancer Research Center	Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7632498B2 (en)	2005-12-19	2009-12-15	Tripath Imaging, Inc.	MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
PT1981902E (pt)	2006-01-27	2015-11-02	Biogen Ma Inc	Antagonistas dos recetores nogo
EP1987360B1 (en)	2006-01-27	2012-03-07	Tripath Imaging, Inc.	Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
WO2007090126A2 (en) *	2006-01-30	2007-08-09	Invitrogen Corporation	Compositions and methods for detecting and quantifying toxic substances in disease states
US20070175313A1 (en) *	2006-01-31	2007-08-02	Kevin Vandervliet	MP3 player holder assembly
US8277816B2 (en) *	2006-02-13	2012-10-02	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
KR20080106434A (ko) *	2006-02-13	2008-12-05	프라운호퍼 유에스에이, 인코포레이티드	Ｈｐｖ 항원, 백신 조성물 및 관련된 방법
US8124103B2 (en) *	2006-02-13	2012-02-28	Fraunhofer Usa, Inc	Influenza antigens, vaccine compositions, and related methods
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
EP2540741A1 (en)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2010569A4 (en)	2006-03-20	2009-09-09	Xoma Technology Ltd	HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
SG170837A1 (en)	2006-04-05	2011-05-30	Abbott Biotech Ltd	Antibody purification
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
EP2007426A4 (en)	2006-04-10	2010-06-16	Abbott Biotech Ltd	COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
EP2666478A3 (en)	2006-04-10	2014-10-22	AbbVie Biotechnology Ltd	Uses and compositions for treatment of psoriasis
US7702468B2 (en)	2006-05-03	2010-04-20	Population Diagnostics, Inc.	Evaluating genetic disorders
US10522240B2 (en)	2006-05-03	2019-12-31	Population Bio, Inc.	Evaluating genetic disorders
AR060871A1 (es) *	2006-05-09	2008-07-16	Genentech Inc	Union de polipeptidos con supercontigos optimizados
EP2027265A1 (en) *	2006-05-30	2009-02-25	Millegen	Highly diversified antibody libraries
GB0611116D0 (en)	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
MX2008015771A (es)	2006-06-14	2009-01-27	Macrogenics Inc	Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
EP2505209A1 (en)	2006-06-26	2012-10-03	MacroGenics, Inc.	Fcgamma-RIIB-specific antibodies and methods of the use thereof
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
CN107243099A (zh)	2006-06-30	2017-10-13	艾伯维生物技术有限公司	自动注射装置
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
KR20140072201A (ko)	2006-07-05	2014-06-12	카탈리스트 바이오사이언시즈, 인코포레이티드	프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
JP2009543862A (ja)	2006-07-14	2009-12-10	ザリージェンツオブザユニバーシティオブカリフォルニア	ガンのバイオマーカーおよびその使用方法
WO2008010101A2 (en)	2006-07-18	2008-01-24	Sanofi-Aventis	Antagonist antibody against epha2 for the treatment of cancer
DK2511301T3 (en)	2006-08-04	2018-03-12	Medimmune Ltd	HUMAN ANTIBODIES AGAINST ERBB 2
EP2064243A2 (en)	2006-08-28	2009-06-03	Kyowa Hakko Kirin Co., Ltd.	Antagonistic human light-specific human monoclonal antibodies
CN101512008B (zh)	2006-09-08	2015-04-01	艾伯维巴哈马有限公司	白介素-13结合蛋白
PT2081595T (pt)	2006-09-26	2019-07-16	Genmab As	Anti-cd38 mais corticosteroides mais um quimioterápico não corticosteroide para tratar tumores
JP5298021B2 (ja)	2006-10-12	2013-09-25	ジェネンテック，インコーポレイテッド	リンホトキシン−αに対する抗体
JP2010506839A (ja)	2006-10-12	2010-03-04	ワイスエルエルシー	乳光の低減を伴う方法および組成物
EP2407548A1 (en)	2006-10-16	2012-01-18	MedImmune, LLC	Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
JP5401319B2 (ja)	2006-11-03	2014-01-29	ワイス・エルエルシー	細胞培養における解糖阻害物質
EP1921142A1 (en) *	2006-11-07	2008-05-14	Cytos Biotechnology AG	Selection of human monoclonal antibodies by eukaryotic cell display
CN101573381A (zh)	2006-11-09	2009-11-04	Irm责任有限公司	激动剂TrkB抗体及其用途
MX2009005026A (es)	2006-11-15	2009-07-31	Functional Genetics Inc	Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.
WO2008064306A2 (en)	2006-11-22	2008-05-29	Curedm, Inc.	Methods and compositions relating to islet cell neogenesis
US7488807B2 (en)	2006-11-22	2009-02-10	3M Innovative Properties Company	Antibody with protein A selectivity
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2099823E (pt)	2006-12-01	2014-12-22	Seattle Genetics Inc	Agentes de ligação ao alvo variantes e suas utilizações
EP2687232A1 (en)	2006-12-06	2014-01-22	MedImmune, LLC	Methods of treating systemic lupus erythematosus
CA2673592C (en)	2006-12-20	2014-03-25	Xoma Technology Ltd.	Methods for the treatment of il-1.beta. related diseases
AU2007339897B2 (en)	2006-12-27	2013-02-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for the treatment of infections and tumors
SI2740744T1 (en)	2007-01-09	2018-06-29	Biogen Ma Inc.	Sp35 antibodies and their use
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
SG177982A1 (en)	2007-01-16	2012-02-28	Abbott Lab	Methods for treating psoriasis
CN102317470A (zh)	2007-02-07	2012-01-11	解码遗传学私营有限责任公司	促进前列腺癌风险的遗传性变型
AU2008216495A1 (en)	2007-02-09	2008-08-21	Genentech, Inc.	Anti-Robo4 antibodies and uses therefor
WO2008101184A2 (en)	2007-02-16	2008-08-21	The Board Of Trustees Of Southern Illinois University	Arl-1 specific antibodies
US8685666B2 (en)	2007-02-16	2014-04-01	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies and uses thereof
CN101668865B (zh)	2007-02-21	2015-05-06	解码遗传学私营有限责任公司	与心血管疾病相关联的遗传易感性变体
WO2008104803A2 (en)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
EP2447719B1 (en)	2007-02-26	2016-08-24	Oxford BioTherapeutics Ltd	Proteins
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
JP5721951B2 (ja)	2007-03-22	2015-05-20	バイオジェンアイデックマサチューセッツインコーポレイテッド	抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
AU2008228085B2 (en)	2007-03-22	2011-12-08	Nxera Pharma Uk Limited	Mutant G-protein coupled receptors and methods for selecting them
CA2682170A1 (en)	2007-03-30	2008-10-09	Medimmune, Llc	Antibodies with decreased deamidation profiles
TW200904470A (en)	2007-04-02	2009-02-01	Pfizer	Anti-IgE antibodies
EP2132339B1 (en) *	2007-04-04	2011-03-09	Chimera Biotec GmbH	Method for the detection of an analyte in biological matrix
US7807168B2 (en) *	2007-04-10	2010-10-05	Vaccinex, Inc.	Selection of human TNFα specific antibodies
CA2683443A1 (en)	2007-04-13	2008-10-23	Catalyst Biosciences, Inc.	Modified factor vii polypeptides and uses thereof
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
EP2152301A4 (en) *	2007-04-28	2010-07-28	Fraunhofer Usa Inc	TRYPANOSOMAANTIGEN, VACCINE COMPOSITIONS AND RELATED METHODS
JP5791895B2 (ja)	2007-05-04	2015-10-07	テクノファージ，インベスティガサンエデセンボルビメントエムビオテクノロジア，エスエー	遺伝子操作されたウサギ抗体可変ドメイン及びその使用
US20080279851A1 (en)	2007-05-07	2008-11-13	Medlmmune, Llc	Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2685222C (en)	2007-05-14	2017-12-19	Medimmune, Llc	Methods of reducing eosinophil levels
MX2009012282A (es)	2007-05-17	2009-11-25	Genentech Inc	Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
NZ581858A (en)	2007-05-25	2012-07-27	Decode Genetics Ehf	Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
US20090232801A1 (en) *	2007-05-30	2009-09-17	Abbot Laboratories	Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) *	2007-05-30	2009-03-27	Abbott Lab	Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EP2171451A4 (en)	2007-06-11	2011-12-07	Abbott Biotech Ltd	METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2631248B9 (en)	2007-06-15	2018-05-23	Medigene AG	Treatment of tumors using specific anti-L1 antibody
ES2975748T3 (es)	2007-06-26	2024-07-12	F Star Therapeutics Ltd	Presentación de agentes de unión
US8404252B2 (en)	2007-07-11	2013-03-26	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
DK2176296T3 (da)	2007-07-16	2012-05-21	Genentech Inc	Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
WO2009012256A1 (en)	2007-07-16	2009-01-22	Genentech, Inc.	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
EP2183378A4 (en)	2007-07-31	2010-09-22	Verenium Corp	CUSTOM MULTI-COMBINED COMBINATION CONSTRUCTION
US20100273722A1 (en) *	2007-08-06	2010-10-28	Yale University	Modified miniature proteins
EP2190472A2 (en) *	2007-08-20	2010-06-02	Fraunhofer USA, Inc.	Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
MY165889A (en) *	2007-08-30	2018-05-18	Curedm Group Holdings Llc	Compositions and methods of using proislet peptides and analogs thereof
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
US12529164B2 (en)	2007-09-14	2026-01-20	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh)	2007-09-14	2014-07-30	阿迪马布有限责任公司	合理设计的合成抗体文库及其用途
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
BRPI0819092A2 (pt) *	2007-11-02	2014-10-14	Scripps Research Inst	Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
DK2219452T3 (en)	2007-11-05	2016-01-11	Medimmune Llc	PROCESSES FOR THE TREATMENT OF scleroderma.
DK2219672T3 (en)	2007-11-09	2016-05-17	Peregrine Pharmaceuticals Inc	The anti-VEGF antibody compositions and methods
CA2705486C (en)	2007-11-19	2019-04-02	Celera Corporation	Lung cancer markers and uses thereof
US9308257B2 (en)	2007-11-28	2016-04-12	Medimmune, Llc	Protein formulation
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8697360B2 (en)	2007-11-30	2014-04-15	Decode Genetics Ehf.	Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
GB0724051D0 (en)	2007-12-08	2008-01-16	Medical Res Council	Mutant proteins and methods for producing them
CA2710373A1 (en) *	2007-12-19	2009-07-09	Ping Tsui	Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
GB0724860D0 (en)	2007-12-20	2008-01-30	Heptares Therapeutics Ltd	Screening
EP2391650B1 (en)	2007-12-20	2014-10-15	Xoma (Us) Llc	Methods for the treatment of gout
JP5690593B2 (ja)	2007-12-26	2015-03-25	ヴァクシネックス，インコーポレイテッド	抗ｃ３５抗体併用療法および方法
CN102016059B (zh)	2007-12-28	2014-10-22	依兰制药公司	淀粉样变性的治疗和预防
GB0800277D0 (en)	2008-01-08	2008-02-13	Imagination Tech Ltd	Video motion compensation
AU2009203350B2 (en)	2008-01-11	2014-03-13	Gene Techno Science Co., Ltd.	Humanized anti-alpha9 integrin antibodies and the uses thereof
BRPI0907046A2 (pt)	2008-01-18	2015-07-28	Medimmune Llc	Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
DK2247620T3 (en)	2008-01-31	2016-08-22	Genentech Inc	ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
WO2009100309A2 (en)	2008-02-08	2009-08-13	Medimmune, Llc	Anti-ifnar1 antibodies with reduced fc ligand affinity
GB0802474D0 (en)	2008-02-11	2008-03-19	Heptares Therapeutics Ltd	Mutant proteins and methods for selecting them
AU2009213689B2 (en)	2008-02-14	2014-11-20	Decode Genetics Ehf.	Susceptibility variants for lung cancer
CN101980723A (zh)	2008-02-28	2011-02-23	3M创新有限公司	艰难梭菌芽孢的抗体及其用途
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en)	2008-03-13	2009-09-17	Dyax Corp	Libraries of genetic packages comprising novel hc cdr3 designs
BRPI0908715A2 (pt)	2008-03-18	2016-05-03	Abbott Lab	métodos para tratamento da psoríase
WO2009118300A1 (en)	2008-03-25	2009-10-01	Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
NZ588905A (en)	2008-04-01	2012-08-31	Decode Genetics Ehf	Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease
AU2009231991B2 (en)	2008-04-02	2014-09-25	Macrogenics, Inc.	HER2/neu-specific antibodies and methods of using same
CN106349390B (zh)	2008-04-02	2019-12-10	宏观基因有限公司	Bcr-复合体-特异性抗体和其使用方法
MY159553A (en)	2008-04-11	2017-01-13	Seattle Genetics Inc	Detection and treatment of pancreatic, ovarian and other cancers
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
AU2009240481B2 (en)	2008-04-24	2015-07-30	Takeda Pharmaceutical Company Limited	Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
CA2721716C (en)	2008-04-24	2019-09-24	Gene Techno Science Co., Ltd.	Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
US20090269786A1 (en) *	2008-04-25	2009-10-29	The Board Of Trustees Of The University Of Illinois	RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
US8273351B2 (en)	2008-04-25	2012-09-25	Dyax Corp.	Fc receptor binding proteins
CN102076355B (zh)	2008-04-29	2014-05-07	Abbvie公司	双重可变结构域免疫球蛋白及其用途
EP2113255A1 (en)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Cytotoxic immunoglobulin
EP2282773B2 (en)	2008-05-02	2025-03-05	Seagen Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CN104558178A (zh)	2008-05-09	2015-04-29	Abbvie公司	针对渐进性糖化终极产物受体（rage）的抗体及其用途
US20100255508A1 (en) *	2008-05-16	2010-10-07	Thomas Richard Gelzleichter	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
US20090291073A1 (en) *	2008-05-20	2009-11-26	Ward Keith W	Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
EP2304439A4 (en)	2008-05-29	2012-07-04	Nuclea Biotechnologies Llc	ANTI-phospho-AKT ANTIBODY
US9109026B2 (en)	2008-06-03	2015-08-18	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
TW201008580A (en)	2008-06-03	2010-03-01	Abbott Lab	Dual variable domain immunoglobulin and uses thereof
EP2282770B1 (en)	2008-06-04	2018-03-07	MacroGenics, Inc.	Antibodies with altered binding to fcrn and methods of using same
CN102316894A (zh)	2008-06-20	2012-01-11	惠氏有限责任公司	来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
WO2010004591A2 (en)	2008-07-07	2010-01-14	Decode Genetics Ehf	Genetic variants for breast cancer risk assessment
TW201014602A (en)	2008-07-08	2010-04-16	Abbott Lab	Prostaglandin E2 binding proteins and uses thereof
JP5674654B2 (ja)	2008-07-08	2015-02-25	アッヴィ・インコーポレイテッド	プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
EP2982695B1 (en)	2008-07-09	2019-04-03	Biogen MA Inc.	Compositions comprising antibodies to lingo or fragments thereof
US8563697B2 (en)	2008-08-14	2013-10-22	Cephalon Australia Pty. Ltd.	Anti-IL-12/IL-23 antibodies
EP3199630B1 (en)	2008-09-05	2019-05-08	President and Fellows of Harvard College	Continuous directed evolution of proteins and nucleic acids
US20100081575A1 (en) *	2008-09-22	2010-04-01	Robert Anthony Williamson	Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
EP2352760A2 (en) *	2008-09-22	2011-08-10	Calmune Corporation	Methods and vectors for display of 2g12-derived domain exchanged antibodies
CA2738019A1 (en)	2008-09-23	2010-04-08	President And Fellows Of Harvard College	Sirt4 and uses thereof
EP2344180A2 (en)	2008-09-23	2011-07-20	Wyeth LLC	Methods for predicting production of activating signals by cross-linked binding proteins
CA2998281C (en)	2008-09-26	2022-08-16	Dana-Farber Cancer Institute, Inc.	Human anti-pd-1 antobodies and uses therefor
WO2010036856A2 (en)	2008-09-26	2010-04-01	Wyeth Llc	Compatible display vector systems
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
EP2341924A4 (en)	2008-10-02	2013-01-23	David Gladstone Inst	METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
SMT202000101T1 (it)	2008-10-10	2020-03-13	Childrens Medical Center	Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
JP2012505900A (ja)	2008-10-14	2012-03-08	ダイアクスコーポレーション	全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
RU2520838C2 (ru)	2008-10-20	2014-06-27	Эббви Инк	Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
AU2009308422B2 (en)	2008-10-24	2017-01-05	The Government of the United States of America as represented by The Secretary, Department of Health and Human Services, Center for Disease Control and Prevention	Human Ebola virus species and compositions and methods thereof
US9393304B2 (en)	2008-10-29	2016-07-19	Ablynx N.V.	Formulations of single domain antigen binding molecules
ES2732504T3 (es)	2008-10-29	2019-11-22	Circular Commitment Company	Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
CA2739352C (en)	2008-10-29	2021-07-13	Wyeth Llc	Methods for purification of single domain antigen binding molecules
CN102438652B (zh)	2008-11-12	2014-08-13	米迪缪尼有限公司	抗体制剂
EP2189539B2 (en)	2008-11-21	2018-06-13	Chimera Biotec GmbH	Conjugate complexes for analyte detection
WO2010062995A2 (en)	2008-11-26	2010-06-03	Five Prime Therapeutics, Inc.	Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
EP2370593B1 (en)	2008-11-28	2016-03-30	Emory University	Methods for determining the efficacy of pd-1 antagonists
RU2011127198A (ru) *	2008-12-04	2013-01-10	Эбботт Лэборетриз	Иммуноглобулины с двойными вариабельными доменами и их применение
EP4331604B9 (en)	2008-12-09	2025-07-23	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
KR20110104032A (ko)	2008-12-19	2011-09-21	마크로제닉스, 인크.	공유결합형 디아바디 및 이의 용도
WO2010078526A1 (en)	2008-12-31	2010-07-08	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
US9181315B2 (en)	2009-01-08	2015-11-10	Dana-Farber Cancer Institute, Inc.	Compositions and methods for induced brown fat differentiation
GB0900425D0 (en)	2009-01-12	2009-02-11	Ucb Pharma Sa	Biological products
EP2387584A1 (en)	2009-01-14	2011-11-23	IQ Therapeutics BV	Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
BRPI1007345A2 (pt)	2009-01-20	2019-04-16	H. ZADEH Homayoun	regeneração óssea de anticorpo mediado
US20120058131A1 (en)	2009-01-21	2012-03-08	Oxford Biotherapeutics Ltd	Pta089 protein
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
RU2011135768A (ru)	2009-01-29	2013-03-10	Эбботт Лэборетриз	Белки, связывающие il-1
WO2010087702A1 (en)	2009-01-30	2010-08-05	Stichting Katholieke Universiteit	TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en)	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
MX2011008697A (es)	2009-02-17	2011-11-18	Ucb Pharma Sa	Moleculas de anticuerpos que tiene especificidad para ox40 humano.
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
WO2010102167A1 (en)	2009-03-05	2010-09-10	Becton, Dickinson And Company	Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
EP2403531A4 (en)	2009-03-05	2013-02-27	Abbott Lab	IL-17 BINDING PROTEINS
CA2753713A1 (en)	2009-03-06	2010-09-10	Tripath Imaging, Inc	Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010100247A1 (en)	2009-03-06	2010-09-10	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Novel therapy for anxiety
CA2754591C (en)	2009-03-10	2018-03-06	Gene Techno Science Co., Ltd.	Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
CN102471380B (zh)	2009-04-01	2015-01-14	霍夫曼-拉罗奇有限公司	抗FcRH5抗体和免疫偶联物及使用方法
NZ595918A (en)	2009-04-03	2013-07-26	Decode Genetics Ehf	Genetic markers for risk management of atrial fibrillation and stroke
EP2241323A1 (en)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W and brain cancers
SG10201401604VA (en)	2009-04-20	2014-08-28	Oxford Biotherapeutics Ltd	Antibodies Specific To Cadherin-17
US20110033389A1 (en) *	2009-04-29	2011-02-10	Zhifeng Chen	Modified antibodies for passive immunotherapy
EP2424891B1 (en)	2009-04-29	2014-06-11	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Erg monoclonal antibodies
NZ595885A (en)	2009-04-29	2014-05-30	Abbvie Biotechnology Ltd	Automatic injection device
MX2011012299A (es) *	2009-05-20	2012-03-29	Novimmune Sa	Librerias de polipeptidos sinteticos y metodos para generar variantes de polipeptido naturalmente diversificadas.
EP2261242A1 (en)	2009-06-10	2010-12-15	Universite Catholique De Louvain	Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
AU2010270979B2 (en)	2009-06-22	2015-04-23	Medimmune, Llc	Engineered Fc regions for site-specific conjugation
GB0910725D0 (en)	2009-06-22	2009-08-05	Heptares Therapeutics Ltd	Mutant proteins and methods for producing them
EP2272979A1 (en)	2009-06-30	2011-01-12	Centre National de la Recherche Scientifique (CNRS)	Method for testing a subject thought to be predisposed to having cancer
JP2012532846A (ja)	2009-07-09	2012-12-20	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	インビボ腫瘍脈管構造画像処理
US8796182B2 (en)	2009-07-10	2014-08-05	Decode Genetics Ehf.	Genetic markers associated with risk of diabetes mellitus
US9259476B2 (en)	2009-07-31	2016-02-16	Wayne State University	Monophosphorylated lipid A derivatives
CN102596220A (zh)	2009-07-31	2012-07-18	韦恩州立大学	单磷酸化的脂质a衍生物
BR112012003064B8 (pt)	2009-08-13	2021-05-25	Crucell Holland Bv	anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
EP2292266A1 (en)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Treating cancer by modulating copine III
TWI465250B (zh)	2009-08-29	2014-12-21	Abbvie Inc	治療用之ｄｌｌ４結合蛋白質
US20110059111A1 (en)	2009-09-01	2011-03-10	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
NZ598929A (en)	2009-09-01	2014-05-30	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
CA2773564A1 (en) *	2009-09-14	2011-03-17	Dyax Corp.	Libraries of genetic packages comprising novel hc cdr3 designs
EP2478101A1 (en)	2009-09-16	2012-07-25	Stichting Het Nederlands Kanker Instituut	Fra-1 target genes as drug targets for treating cancer
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
EP2305717A1 (en)	2009-09-21	2011-04-06	Koninklijke Nederlandse Akademie van Wetenschappen	Inhibiting TNIK for treating colon cancer
EP2480573A1 (en)	2009-09-22	2012-08-01	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
EP2480572B1 (en)	2009-09-25	2019-01-30	The United States of America, as represented by The Secretary, Department of Health and Human Services	Neutralizing antibodies to hiv-1 and their use
US9598692B2 (en)	2009-09-25	2017-03-21	University Of Oslo	Multivalent phage display systems and methods
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
JP5885664B2 (ja)	2009-09-25	2016-03-15	ゾーマテクノロジーリミテッド	スクリーニング法
CA2776144C (en)	2009-09-29	2020-10-27	Fraunhofer Usa, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
EP2483406A2 (en)	2009-09-30	2012-08-08	President and Fellows of Harvard College	Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
TW201116297A (en)	2009-10-02	2011-05-16	Sanofi Aventis	Antibodies that specifically bind to the EphA2 receptor
US20120231004A1 (en)	2009-10-13	2012-09-13	Oxford Biotherapeutic Ltd.	Antibodies
BR112012008833A2 (pt)	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
RS60577B1 (sr)	2009-10-20	2020-08-31	Abbvie Inc	Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
US9234037B2 (en)	2009-10-27	2016-01-12	Ucb Biopharma Sprl	Method to generate antibodies to ion channels
US20110098862A1 (en)	2009-10-27	2011-04-28	ExxonMobil Research Engineering Company Law Department	Multi-stage processes and control thereof
GB0922435D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	Method
GB0922434D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
EP2493926B1 (en)	2009-10-27	2020-03-11	UCB Biopharma SRL	Function modifying nav 1.7 antibodies
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
US8420083B2 (en)	2009-10-31	2013-04-16	Abbvie Inc.	Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US20120282177A1 (en)	2009-11-02	2012-11-08	Christian Rohlff	ROR1 as Therapeutic and Diagnostic Target
US9244063B2 (en)	2009-11-11	2016-01-26	Gentian As	Immunoassay for assessing related analytes of different origin
EP3168232B1 (en)	2009-11-13	2021-09-29	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
WO2011062862A1 (en) *	2009-11-17	2011-05-26	Centocor Ortho Biotech Inc.	Improved bacterial membrane protein secrection
GB0920324D0 (en)	2009-11-19	2010-01-06	Ucb Pharma Sa	Antibodies
ES2562832T3 (es)	2009-12-08	2016-03-08	Abbvie Deutschland Gmbh & Co Kg	Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
RS62853B1 (sr)	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
WO2011088163A1 (en)	2010-01-14	2011-07-21	President And Fellows Of Harvard College	Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
EP2526424A2 (en)	2010-01-22	2012-11-28	Dana-Farber Cancer Institute, Inc.	Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
CA2789168A1 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
EP2354245A1 (en)	2010-02-04	2011-08-10	Stichting Top Institute Food and Nutrition	MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en)	2010-02-04	2011-08-10	Stichting Top Institute Food and Nutrition	MBL2 as a marker of liver-specific insulin resistance
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
EP2542582A4 (en)	2010-03-02	2013-12-04	Abbvie Inc	THERAPEUTIC PROTEINS LINKING TO DLL4
BR112012022342A2 (pt) *	2010-03-04	2017-02-14	Vet Therapeutics Inc	anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) *	2010-03-04	2017-04-11	Vet Therapeutics, Inc.	Monoclonal antibodies directed to CD20
WO2011107586A1 (en)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, tenascin-c and brain cancers
WO2013040142A2 (en)	2011-09-16	2013-03-21	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
US10706955B2 (en)	2010-03-23	2020-07-07	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
GB201005064D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US10472426B2 (en)	2010-03-25	2019-11-12	Ucb Biopharma Sprl	Disulfide stabilized DVD-Ig molecules
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
EP3540059A1 (en)	2010-04-16	2019-09-18	Nuevolution A/S	Bi-functional complexes and methods for making and using such complexes
WO2011131611A1 (en)	2010-04-19	2011-10-27	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Modulating xrn1
EP2380909A1 (en)	2010-04-26	2011-10-26	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	PTK-7 protein involved in breast cancer
EP3508854A1 (en)	2010-04-27	2019-07-10	The Regents of The University of California	Cancer biomarkers and methods of use thereof
PT2563813E (pt)	2010-04-30	2015-11-26	Alexion Pharma Inc	Anticorpos anti-c5a e métodos para utilização dos anticorpos
PT3103478T (pt)	2010-04-30	2019-07-10	Janssen Biotech Inc	Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
US20110293629A1 (en)	2010-05-14	2011-12-01	Bastid Jeremy	Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
KR101848225B1 (ko)	2010-05-14	2018-04-12	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
CN103079594B (zh)	2010-06-03	2016-04-13	艾伯维生物技术有限公司	用于治疗化脓性汗腺炎(hs)的用途和组合物
WO2012047324A2 (en)	2010-06-10	2012-04-12	President And Fellows Of Harvard College	Systems and methods for amplification and phage display
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
AU2011268310A1 (en)	2010-06-16	2013-01-10	Abbvie Inc.	Comparison of protein samples
WO2011163314A1 (en)	2010-06-22	2011-12-29	Regeneron Pharmaceuticals, Inc.	Hybrid light chain mice
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
US9139642B2 (en)	2010-07-09	2015-09-22	Crucell Holland B.V.	Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
JP2013539962A (ja)	2010-07-09	2013-10-31	ジェネンテック，インコーポレイテッド	抗ニューロピリン抗体及び使用方法
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
DK2593594T3 (en)	2010-07-16	2017-12-11	Adimab Llc	ANTIBODY LIBRARIES
JP2013536175A (ja)	2010-07-16	2013-09-19	アブリンクスエン．ヴェー．	修飾された単一ドメイン抗原結合分子及びその使用
ES2667100T3 (es)	2010-08-02	2018-05-09	Macrogenics, Inc.	Diacuerpos covalentes y sus usos
WO2012018387A2 (en)	2010-08-02	2012-02-09	Population Diagnotics, Inc.	Compositions and methods for discovery of causative mutations in genetic disorders
PE20131412A1 (es)	2010-08-03	2014-01-19	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
EP2420250A1 (en)	2010-08-13	2012-02-22	Universitätsklinikum Münster	Anti-Syndecan-4 antibodies
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
HUE031695T2 (en)	2010-08-17	2017-07-28	Stichting Katholieke Univ	New method for diagnosing Q-fever using a cellular immunological test
LT3333188T (lt)	2010-08-19	2022-06-10	Zoetis Belgium S.A.	Anti-ngf antikūnai ir jų panaudojimas
GB201014033D0 (en)	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
EP2608803A4 (en)	2010-08-26	2014-01-15	Abbvie Inc	IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
SG10201506782XA (en)	2010-08-27	2015-10-29	Stem Centrx Inc	Notum protein modulators and methods of use
JP6327855B2 (ja)	2010-09-03	2018-05-23	アッヴィ・ステムセントルクス・エル・エル・シー	新規モジュレータ及びその使用法
US20130171159A1 (en)	2010-09-10	2013-07-04	Brian Arthur Hemmings	Phosphorylated twist1 and metastasis
BR112013006403A2 (pt)	2010-09-20	2015-09-29	Abbvie Inc	purificação de anticorpos usando cromatografia de leito móvel simulado
DK2619584T3 (en)	2010-09-21	2017-01-09	Stichting Katholieke Univ	New method for the diagnosis of Lyme disease using a cellular immunological tests
US9005907B2 (en)	2010-10-01	2015-04-14	St. Jude Children's Research Hospital	Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012052391A1 (en)	2010-10-19	2012-04-26	Glaxo Group Limited	Polypeptide with jmjd3 catalytic activity
BR112013010535A2 (pt)	2010-10-27	2017-11-07	Univ New York State Res Found	composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer
WO2012065937A1 (en)	2010-11-15	2012-05-24	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Anti-fungal agents
US9072766B2 (en)	2010-11-18	2015-07-07	Beth Israel Deaconess Medical Center, Inc.	Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
CA2820885A1 (en)	2010-12-08	2012-09-07	Stem Centrx, Inc.	Novel modulators and methods of use
EP2465928A1 (en)	2010-12-16	2012-06-20	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Treatment of Th17-mediated diseases
US20120275996A1 (en)	2010-12-21	2012-11-01	Abbott Laboratories	IL-1 Binding Proteins
BR112013015944A2 (pt)	2010-12-21	2018-06-19	Abbvie Inc	imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
WO2012088381A2 (en)	2010-12-22	2012-06-28	President And Fellows Of Harvard College	Continuous directed evolution
JP6147670B2 (ja)	2010-12-22	2017-06-14	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	改善された半減期を有する修飾された抗体
WO2012092323A1 (en)	2010-12-28	2012-07-05	Xoma Technology Ltd.	Cell surface display using pdz domains
US9598499B2 (en)	2010-12-30	2017-03-21	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
CN103384682B (zh)	2011-01-14	2017-04-12	Ucb医药有限公司	结合il‑17a和il‑17f的抗体分子
WO2012103141A1 (en)	2011-01-24	2012-08-02	Abbott Biotechnology Ltd.	Automatic injection devices having overmolded gripping surfaces
US9540443B2 (en)	2011-01-26	2017-01-10	Kolltan Pharmaceuticals, Inc.	Anti-kit antibodies
US9956236B2 (en)	2011-02-07	2018-05-01	Cornell University	Methods for increasing immune responses using agents that directly bind to and activate IRE-1
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
JP6105491B2 (ja)	2011-03-02	2017-03-29	バーグエルエルシー	照合性細胞ベースのアッセイ及びその使用
EP2683837A2 (en)	2011-03-07	2014-01-15	University Of Louisville Research Foundation, Inc.	Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
US20120238730A1 (en)	2011-03-15	2012-09-20	Abbott Laboratories	Integrated approach to the isolation and purification of antibodies
TW201239355A (en)	2011-03-23	2012-10-01	Abbott Lab	Methods and systems for the analysis of protein samples
AU2012237287B2 (en)	2011-03-30	2016-09-08	Ablynx Nv	Methods of treating immune disorders with single domain antibodies against TNF-alpha
WO2012134813A1 (en)	2011-03-31	2012-10-04	St. Jude Children's Research Hospital	Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
NZ616308A (en)	2011-04-08	2016-03-31	Biogen Ma Inc	Biomarkers predictive of therapeutic responsiveness to ifnβ and uses thereof
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
PT2699264T (pt)	2011-04-20	2018-05-23	Medimmune Llc	Anticorpos e outras moléculas que ligam b7-h1 e pd-1
WO2012162068A2 (en)	2011-05-21	2012-11-29	Macrogenics, Inc.	Deimmunized serum-binding domains and their use for extending serum half-life
CN103619353B (zh)	2011-06-02	2016-01-06	戴埃克斯有限公司	Fc受体结合蛋白
PL2714735T3 (pl)	2011-06-03	2022-02-21	Xoma Technology Ltd.	Przeciwciała swoiste dla tgf-beta
WO2012168259A1 (en)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
WO2012170740A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
KR102111171B1 (ko)	2011-06-10	2020-05-14	메디뮨 엘엘씨	항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
MY177267A (en)	2011-06-28	2020-09-10	Berlin Chemie Ag	Antibodies
ES2615256T3 (es)	2011-06-28	2017-06-06	Oxford Biotherapeutics Ltd.	Objetivo terapéutico y de diagnóstico
HK1198328A1 (zh)	2011-07-13	2015-04-02	Abbvie Inc.	使用抗il-13抗體治療哮喘的方法和組合物
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
US10323236B2 (en)	2011-07-22	2019-06-18	President And Fellows Of Harvard College	Evaluation and improvement of nuclease cleavage specificity
US9676854B2 (en)	2011-08-15	2017-06-13	Medimmune, Llc	Anti-B7-H4 antibodies and their uses
EP2748192B2 (en)	2011-08-23	2022-04-20	Foundation Medicine, Inc.	Kif5b-ret fusion molecules and uses thereof
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US20140234903A1 (en)	2011-09-05	2014-08-21	Eth Zurich	Biosynthetic gene cluster for the production of peptide/protein analogues
WO2013034660A1 (en)	2011-09-09	2013-03-14	Medimmune Limited	Anti-siglec-15 antibodies and uses thereof
CA2848368C (en)	2011-09-13	2023-02-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for brown fat induction and activity using fndc5
DK2766483T3 (da)	2011-10-10	2022-04-19	Hospital For Sick Children	Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
WO2013056178A2 (en)	2011-10-14	2013-04-18	Foundation Medicine, Inc.	Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
TW201326207A (zh)	2011-10-24	2013-07-01	Abbvie Inc	抗ｔｎｆ免疫結合物
TW201323440A (zh)	2011-10-24	2013-06-16	Abbvie Inc	抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
WO2013067055A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Methods of blocking cancer stem cell growth
US9221906B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of inhibiting solid tumor growth by administering GPR49 antibodies
AU2012332590B2 (en)	2011-11-01	2016-10-20	Bionomics, Inc.	Anti-GPR49 antibodies
WO2013067060A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
JP6301258B2 (ja)	2011-11-03	2018-03-28	トライパスイメージングインコーポレイテッド	免疫染色試料を調製するための方法および構成物
DK2773779T3 (da)	2011-11-04	2020-11-23	Population Bio Inc	Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
KR102184343B1 (ko)	2011-11-07	2020-11-30	메디뮨 엘엘씨	항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
US20140294732A1 (en)	2011-11-08	2014-10-02	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en)	2011-11-08	2013-05-16	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
BR112014011115A2 (pt)	2011-11-08	2017-06-13	Pfizer	métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
CN103946237B (zh)	2011-11-11	2017-04-12	Ucb医药有限公司	白蛋白结合抗体及其结合片段
AU2012346861A1 (en)	2011-11-30	2014-06-19	AbbVie Deutschland GmbH & Co. KG	Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
MX356933B (es)	2011-12-14	2018-06-20	Abbvie Deutschland	Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
CN107459576A (zh)	2011-12-14	2017-12-12	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
EP3050900A1 (en)	2011-12-19	2016-08-03	Xoma (Us) Llc	Methods for treating acne
KR102038974B1 (ko)	2011-12-20	2019-10-31	리제너론 파마슈티칼스 인코포레이티드	인간화 경쇄 마우스
CA2859755C (en)	2011-12-23	2021-04-20	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
UY34558A (es)	2011-12-30	2013-07-31	Abbvie Inc	Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
EP2800583A1 (en)	2012-01-02	2014-11-12	Novartis AG	Cdcp1 and breast cancer
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
MY194587A (en)	2012-01-27	2022-12-05	Abbvie Inc	Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
WO2013120018A1 (en)	2012-02-09	2013-08-15	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
AU2013216863B2 (en)	2012-02-10	2018-09-06	Seagen Inc.	Detection and treatment of CD30+ cancers
RS56593B1 (sr)	2012-02-15	2018-02-28	Novo Nordisk As	Antitela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloidnim ćelijama-1 (trem-1)
LT2814842T (lt)	2012-02-15	2018-11-12	Novo Nordisk A/S	Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
GB201203051D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
JP6089047B2 (ja)	2012-02-24	2017-03-01	アッヴィ・ステムセントルクス・エル・エル・シー	Ｄｌｌ３モジュレーター及び使用方法
MX2014010750A (es)	2012-03-08	2015-02-05	Halozyme Inc	Anticuerpos receptores del factor de crecimiento anti-epidermico condicionalmente activos y metodos de uso de los mismos.
WO2013138522A2 (en)	2012-03-16	2013-09-19	Genelux Corporation	Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013142808A1 (en)	2012-03-23	2013-09-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
US20150266961A1 (en)	2012-03-29	2015-09-24	Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute	Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
MX357392B (es)	2012-04-02	2018-07-06	Berg Llc	Ensayos basados en interrogatorios celulares y uso de los mismos.
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
WO2013158275A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Cell culture methods to reduce acidic species
CN114163530B (zh)	2012-04-20	2025-04-29	美勒斯公司	用于产生免疫球蛋白样分子的方法和手段
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
AU2013262934B2 (en)	2012-05-14	2018-02-01	Biogen Ma Inc.	LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2013172951A1 (en)	2012-05-15	2013-11-21	Morphotek, Inc.	Methods for treatment of gastric cancer
WO2013177115A2 (en)	2012-05-21	2013-11-28	Abbvie Inc.	Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
EP2859018B1 (en)	2012-06-06	2021-09-22	Zoetis Services LLC	Caninized anti-ngf antibodies and methods thereof
US10048253B2 (en)	2012-06-28	2018-08-14	Ucb Biopharma Sprl	Method for identifying compounds of therapeutic interest
US20150218238A1 (en)	2012-06-29	2015-08-06	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en)	2012-07-05	2015-07-02	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	New treatment for neurodegenerative diseases
US20150224190A1 (en)	2012-07-06	2015-08-13	Mohamed Bentires-Alj	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
GB201213652D0 (en)	2012-08-01	2012-09-12	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
ES2771324T3 (es)	2012-08-03	2020-07-06	Dana Farber Cancer Inst Inc	Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
WO2014039860A2 (en)	2012-09-07	2014-03-13	University Of Louisville Research Foundation, Inc.	Compositions and methods for modulating dnmt1 inhibitor activity
DK2895621T3 (da)	2012-09-14	2020-11-30	Population Bio Inc	Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en)	2012-09-27	2014-04-03	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
AR092745A1 (es)	2012-10-01	2015-04-29	Univ Pennsylvania	Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
KR20210063443A (ko)	2012-10-09	2021-06-01	바이오젠 엠에이 인코포레이티드	탈수초성 질환의 치료를 위한 복합 요법 및 용도
EP2906241B1 (en)	2012-10-12	2020-01-08	The Brigham and Women's Hospital, Inc.	Enhancement of the immune response
KR20190096459A (ko)	2012-11-01	2019-08-19	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
US20150291953A1 (en) *	2012-11-02	2015-10-15	Enzymatics Inc.	Methods and kits for nucleic acid sample preparation for sequencing
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
ES2949394T3 (es)	2012-11-05	2023-09-28	Found Medicine Inc	Moléculas de fusión novedosas y usos de las mismas
MX2015005831A (es)	2012-11-08	2015-09-24	Eleven Biotherapeutics Inc	Antagonistas de il-6 y usos de los mismos.
WO2014074942A1 (en)	2012-11-08	2014-05-15	Illumina, Inc.	Risk variants of alzheimer's disease
SMT202000193T1 (it)	2012-12-10	2020-05-08	Biogen Ma Inc	Anticorpi anti-antigene 2 delle cellule dendritiche del sangue e loro usi
AU2013363962B2 (en)	2012-12-21	2016-11-24	Amplimmune, Inc.	Anti-H7CR antibodies
US9550986B2 (en)	2012-12-21	2017-01-24	Abbvie Inc.	High-throughput antibody humanization
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
AU2013202668B2 (en)	2012-12-24	2014-12-18	Adelaide Research & Innovation Pty Ltd	Inhibition of cancer growth and metastasis
US10717965B2 (en)	2013-01-10	2020-07-21	Gloriana Therapeutics, Inc.	Mammalian cell culture-produced neublastin antibodies
CA3150658A1 (en)	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
SMT201900339T1 (it)	2013-02-22	2019-07-11	Medimmune Ltd	Coniugati anticorpo anti-dll3/pbd e loro usi
WO2014142646A1 (en)	2013-03-13	2014-09-18	Stichting Katholieke Universiteit	Q-fever diagnostic
CN105452292A (zh)	2013-03-14	2016-03-30	帕卡什·吉尔	使用结合细胞表面grp78的抗体进行癌症治疗
BR112015023355A8 (pt)	2013-03-14	2018-01-30	Abbott Lab	antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
BR112015023239A8 (pt)	2013-03-14	2018-04-17	Abbott Lab	ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
WO2014142882A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Protein purification using displacement chromatography
CA2899449A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	Low acidic species compositions and methods for producing the same using displacement chromatography
EP2836515A1 (en)	2013-03-14	2015-02-18	AbbVie Inc.	Low acidic species compositions and methods for producing and using the same
WO2014143343A1 (en)	2013-03-14	2014-09-18	Abbott Laboratories	Hcv core lipid binding domain monoclonal antibodies
WO2014144292A2 (en)	2013-03-15	2014-09-18	Sanofi Pasteur Biologics , Llc	Antibodies against clostridium difficile toxins and methods of using the same
TW201945032A (zh)	2013-03-15	2019-12-01	德商艾伯維德國有限及兩合公司	抗-egfr抗體藥物結合物調配物
KR20150132864A (ko)	2013-03-15	2015-11-26	애브비 인코포레이티드	항체 약물 접합체(adc) 정제
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
JP2016515120A (ja)	2013-03-15	2016-05-26	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
BR112015023797A2 (pt)	2013-03-15	2017-10-24	Abbvie Inc	proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US9499621B2 (en)	2013-04-08	2016-11-22	Cytodyn, Inc.	Felinized antibodies and methods of treating retroviral infections in felines
EP2992333A1 (en)	2013-05-02	2016-03-09	Stichting Katholieke Universiteit	Personalised medicine
PT2981822T (pt)	2013-05-06	2020-12-07	Scholar Rock Inc	Composições e métodos para modulação do fator de crescimento
KR20160021125A (ko)	2013-05-17	2016-02-24	쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스)	항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
AU2014268298B2 (en)	2013-05-24	2019-01-17	Medlmmune, Llc	Anti-B7-H5 antibodies and their uses
EP3293275B1 (en)	2013-06-06	2021-08-04	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
SG11201509982UA (fi)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
WO2014197885A2 (en)	2013-06-07	2014-12-11	Duke University	Inhibitors of complement factor h
EP3027225B1 (en)	2013-07-31	2021-03-24	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating thermogenesis using transforming growth factor alpha
WO2015019286A1 (en)	2013-08-07	2015-02-12	Friedrich Miescher Institute For Biomedical Research	New screening method for the treatment friedreich's ataxia
US9163284B2 (en)	2013-08-09	2015-10-20	President And Fellows Of Harvard College	Methods for identifying a target site of a Cas9 nuclease
EP3036320B2 (en)	2013-08-19	2024-04-03	Biogen MA Inc.	Control of protein glycosylation by culture medium supplementation and cell culture process parameters
EP3041507B1 (en)	2013-08-26	2021-06-30	BioNTech Research and Development, Inc.	Nucleic acids encoding human antibodies to sialyl-lewis a
JP2016538318A (ja)	2013-08-28	2016-12-08	ステムセントリックス，インコーポレイテッド	新規ｓｅｚ６モジュレーターおよび使用方法
EP3892294A1 (en)	2013-08-28	2021-10-13	AbbVie Stemcentrx LLC	Site-specific antibody conjugation methods and compositions
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
HK1226081A1 (zh)	2013-09-12	2017-09-22	Halozyme, Inc.	修饰的抗表皮生长因子受体抗体及其使用方法
EP3049521B1 (en)	2013-09-25	2019-03-06	Cornell University	Compounds for inducing anti-tumor immunity and methods thereof
HUE057005T2 (hu)	2013-09-25	2022-04-28	Bioverativ Therapeutics Inc	Oszlopon történõ vírusinaktiváló eljárások
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
WO2015057939A1 (en)	2013-10-18	2015-04-23	Biogen Idec Ma Inc.	Anti-s1p4 antibodies and uses thereof
CA3120508A1 (en)	2013-10-28	2015-05-07	Dots Technology Corp.	Allergen detection
EP3777980B1 (en)	2013-10-29	2023-12-06	President and Fellows of Harvard College	Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration
EP2871189A1 (en)	2013-11-07	2015-05-13	Institut Pasteur	High-affinity monoclonal anti-strep-tag antibody
WO2015070068A1 (en)	2013-11-07	2015-05-14	Abbvie Inc.	Isolation and purification of antibodies
FI3511422T3 (fi)	2013-11-12	2023-01-31		Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten
WO2015071759A1 (en)	2013-11-15	2015-05-21	Institut Pasteur	A molecular marker of plasmodium falciparum artemisinin resistance
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
JP6779785B2 (ja)	2013-12-19	2020-11-04	ノバルティスアーゲー	ヒトメソテリンキメラ抗原受容体およびその使用
US11708411B2 (en)	2013-12-20	2023-07-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US20160289633A1 (en)	2013-12-20	2016-10-06	Biogen Ma Inc.	Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
EP2960252A1 (en)	2014-06-26	2015-12-30	Institut Pasteur	Phospholipase for treatment of immunosuppression
SI3712174T1 (sl)	2013-12-24	2022-06-30	Janssen Pharmaceutica Nv	Protitelesa in delci proti VISTA
US10238700B2 (en)	2014-01-02	2019-03-26	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
AU2015206603B9 (en)	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
WO2015134121A2 (en)	2014-01-20	2015-09-11	President And Fellows Of Harvard College	Negative selection and stringency modulation in continuous evolution systems
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2938590C (en)	2014-02-11	2023-10-17	Visterra, Inc.	Antibody molecules to dengue virus and uses thereof
BR112016018891A2 (pt)	2014-02-21	2017-10-10	Abbvie Stemcentrx Llc	anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
LT3116909T (lt)	2014-03-14	2020-02-10	Novartis Ag	Antikūno molekulės prieš lag-3 ir jų panaudojimas
US9738702B2 (en)	2014-03-14	2017-08-22	Janssen Biotech, Inc.	Antibodies with improved half-life in ferrets
DK3122869T3 (da)	2014-03-24	2019-09-09	Biogen Ma Inc	Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
EP3125938A4 (en)	2014-03-31	2017-08-23	The Johns Hopkins University	Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
MX2016012873A (es)	2014-04-04	2017-03-07	Bionomics Inc	Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
ES2851451T3 (es)	2014-05-13	2021-09-07	Bavarian Nordic As	Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
CN106413750B (zh)	2014-05-16	2022-04-29	免疫医疗有限责任公司	具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
SMT202100116T1 (it)	2014-05-28	2021-05-07	Agenus Inc	Anticorpi anti-gitr e metodi di utilizzo degli stessi
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
NZ726911A (en)	2014-06-03	2023-01-27	Xbiotech Inc	Compositions and methods for treating and preventing staphylococcus aureus infections
AU2015271685B2 (en)	2014-06-04	2021-02-18	Biontech Research And Development, Inc.	Human monoclonal antibodies to ganglioside GD2
WO2015189816A1 (en)	2014-06-13	2015-12-17	Friedrich Miescher Institute For Biomedical Research	New treatment against influenza virus
WO2015198202A1 (en)	2014-06-23	2015-12-30	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
US20170165261A1 (en)	2014-07-01	2017-06-15	Brian Arthur Hemmings	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
TN2017000008A1 (en)	2014-07-17	2018-07-04	Novo Nordisk As	Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
BR112017001242A2 (pt)	2014-07-21	2017-12-05	Novartis Ag	tratamento de câncer usando um receptor antigênico quimérico a cd33
EP3511413B1 (en)	2014-07-25	2022-09-07	Theravectys	Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US10077453B2 (en)	2014-07-30	2018-09-18	President And Fellows Of Harvard College	CAS9 proteins including ligand-dependent inteins
US10851149B2 (en)	2014-08-14	2020-12-01	The Trustees Of The University Of Pennsylvania	Treatment of cancer using GFR α-4 chimeric antigen receptor
TW202140557A (zh)	2014-08-19	2021-11-01	瑞士商諾華公司	使用cd123嵌合抗原受體治療癌症
PL3186281T3 (pl)	2014-08-28	2019-10-31	Halozyme Inc	Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
US10724096B2 (en)	2014-09-05	2020-07-28	Population Bio, Inc.	Methods and compositions for inhibiting and treating neurological conditions
CA2960824A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
CN107001471B (zh)	2014-09-16	2022-01-18	西福根有限公司	抗met抗体和组合物
WO2016046768A1 (en)	2014-09-24	2016-03-31	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
EP3200822B1 (en)	2014-09-30	2021-04-14	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Binding molecules, especially antibodies, binding to l1cam (cd171)
WO2016050867A1 (en)	2014-10-01	2016-04-07	Medimmune Limited	Antibodies to ticagrelor and methods of use
ES2774448T3 (es)	2014-10-03	2020-07-21	Novartis Ag	Terapias de combinación
JP6877339B2 (ja)	2014-10-14	2021-05-26	ノバルティスアーゲー	Ｐｄ−ｌ１に対する抗体分子およびその使用
MA41685A (fr)	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
US10920208B2 (en)	2014-10-22	2021-02-16	President And Fellows Of Harvard College	Evolution of proteases
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
SG11201703667SA (en)	2014-11-05	2017-06-29	Annexon Inc	Humanized anti-complement factor c1q antibodies and uses thereof
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
PH12017500809B1 (en)	2014-11-07	2023-09-20	F Hoffmann La Roche Ltd	Improved il-6 antibodies
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
ES2941897T3 (es)	2014-11-12	2023-05-26	Seagen Inc	Compuestos que interaccionan con glicanos y procedimientos de uso
WO2016081835A2 (en)	2014-11-21	2016-05-26	University Of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
WO2016090323A1 (en)	2014-12-05	2016-06-09	Prelude, Inc.	Dcis recurrence and invasive breast cancer
AU2015360903B2 (en)	2014-12-08	2021-03-25	Dana-Farber Cancer Institute, Inc.	Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
WO2016094837A2 (en)	2014-12-11	2016-06-16	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
WO2016100882A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Combination therapies
EP3237450B1 (en)	2014-12-22	2021-03-03	The Rockefeller University	Anti-mertk agonistic antibodies and uses thereof
WO2016112270A1 (en)	2015-01-08	2016-07-14	Biogen Ma Inc.	Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3253793A4 (en)	2015-02-02	2018-11-14	i2 Pharmaceuticals, Inc.	Anti-surrogate light chain antibodies
WO2016141111A1 (en)	2015-03-03	2016-09-09	Xoma (Us) Llc	Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
DE112016001013T5 (de)	2015-03-03	2017-12-21	Kymab Limited	Antikörper, verwendungen und verfahren
ES2805206T3 (es)	2015-03-10	2021-02-11	Univ Massachusetts	Enfoque dirigido a GDF6 y a señalización de BMP para la terapia contra el melanoma
CN107530427A (zh)	2015-03-27	2018-01-02	南加利福尼亚大学	针对用于实体肿瘤的治疗的lhr的car t细胞疗法
JP6901400B2 (ja)	2015-04-03	2021-07-14	ゾーマテクノロジーリミテッド	ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
US10125198B2 (en)	2015-04-17	2018-11-13	Distributed Bio, Inc.	Method for mass humanization of non-human antibodies
US11299729B2 (en)	2015-04-17	2022-04-12	President And Fellows Of Harvard College	Vector-based mutagenesis system
US10954515B2 (en)	2015-04-21	2021-03-23	Institut Gustave Roussy	Therapeutic methods, products and compositions inhibiting ZNF555
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
AU2016256486B2 (en)	2015-04-29	2021-09-23	University Of South Australia	Compositions and methods for administering antibodies
EP3288973B1 (en)	2015-04-30	2021-10-20	AbCheck s.r.o.	Method for mass humanization of rabbit antibodies
BR112017023829A2 (pt)	2015-05-06	2018-07-31	Janssen Biotech Inc	agentes de ligação biespecíficos de antígeno de membrana específico da próstata (psma) e usos dos mesmos
CN115109158A (zh)	2015-05-07	2022-09-27	阿吉纳斯公司	抗ox40抗体及其使用方法
EP3303390A1 (en)	2015-05-27	2018-04-11	UCB Biopharma SPRL	Method for the treatment of neurological disease
PE20180193A1 (es)	2015-05-29	2018-01-26	Abbvie Inc	Anticuerpos anti-cd40 y sus usos
DK3303394T3 (da)	2015-05-29	2020-07-06	Agenus Inc	Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016197064A1 (en)	2015-06-04	2016-12-08	Epstein Alan L	Lym-1 and lym-2 targeted car cell immunotherapy
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
WO2016207717A1 (en)	2015-06-24	2016-12-29	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
WO2017015545A1 (en)	2015-07-22	2017-01-26	President And Fellows Of Harvard College	Evolution of site-specific recombinases
US11524983B2 (en)	2015-07-23	2022-12-13	President And Fellows Of Harvard College	Evolution of Bt toxins
EP3964528A1 (en)	2015-07-29	2022-03-09	Novartis AG	Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en)	2015-07-29	2021-09-15	Novartis AG	Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
US10612011B2 (en)	2015-07-30	2020-04-07	President And Fellows Of Harvard College	Evolution of TALENs
CA2994841A1 (en)	2015-08-06	2017-02-09	Xoma (Us) Llc	Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
EP3341415B1 (en)	2015-08-28	2021-03-24	H. Hoffnabb-La Roche Ag	Anti-hypusine antibodies and uses thereof
WO2017040790A1 (en)	2015-09-01	2017-03-09	Agenus Inc.	Anti-pd-1 antibodies and methods of use thereof
AU2016323447B2 (en)	2015-09-15	2023-03-30	Scholar Rock, Inc.	Anti-pro/latent-Myostatin antibodies and uses thereof
AU2016326721C1 (en)	2015-09-23	2021-06-03	Cytoimmune Therapeutics, Inc.	FLT3 directed car cells for immunotherapy
CA2992602A1 (en)	2015-09-23	2017-03-30	Genentech, Inc.	Optimized variants of anti-vegf antibodies
WO2017066561A2 (en)	2015-10-16	2017-04-20	President And Fellows Of Harvard College	Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US10167457B2 (en)	2015-10-23	2019-01-01	President And Fellows Of Harvard College	Nucleobase editors and uses thereof
SG11201802887PA (en)	2015-10-27	2018-05-30	Ucb Biopharma Sprl	Methods of treatment using anti-il-17a/f antibodies
EP3368566A1 (en)	2015-10-28	2018-09-05	Friedrich Miescher Institute for Biomedical Research	Tenascin-w and biliary tract cancers
CA3002676A1 (en)	2015-10-29	2017-05-04	Dana-Farber Cancer Institute, Inc.	Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
EP3374391B1 (en)	2015-11-10	2024-04-17	Visterra, Inc.	Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
SG11201803213XA (en)	2015-11-12	2018-05-30	Siamab Therapeutics Inc	Glycan-interacting compounds and methods of use
MX2018006385A (es)	2015-11-25	2019-09-11	Visterra Inc	Moleculas de anticuerpo contra april y usos de las mismas.
EP3909983A1 (en)	2015-12-02	2021-11-17	STCube & Co. Inc.	Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP7227007B2 (ja)	2015-12-02	2023-02-21	ストサイエンシス，インコーポレイテッド	グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
EP3386542B1 (en)	2015-12-10	2020-11-18	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
EP4424322A3 (en)	2015-12-17	2025-04-16	Novartis AG	Antibody molecules to pd-1 and uses thereof
EP3389713A2 (en)	2015-12-17	2018-10-24	Novartis AG	Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
SG11201805709RA (en)	2016-01-08	2018-07-30	Scholar Rock Inc	Anti-pro/latent myostatin antibodies and methods of use thereof
GB201602413D0 (en)	2016-02-10	2016-03-23	Nascient Ltd	Method
CN109069626A (zh)	2016-02-12	2018-12-21	詹森药业有限公司	抗-vista(b7h5)抗体
JP2019510078A (ja)	2016-02-23	2019-04-11	セセンバイオ，インコーポレイテッド	Ｉｌ−６アンタゴニスト製剤およびその使用
KR20180119632A (ko)	2016-02-29	2018-11-02	제넨테크, 인크.	암에 대한 치료 및 진단 방법
AU2017225869A1 (en)	2016-02-29	2018-09-06	Foundation Medicine, Inc.	Methods of treating cancer
CA3017197A1 (en)	2016-03-10	2017-09-14	Viela Bio, Inc.	Ilt7 binding molecules and methods of using the same
US11643459B2 (en)	2016-03-11	2023-05-09	Scholar Rock, Inc.	TGFβ1-binding immunoglobulins and use thereof
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
WO2017161206A1 (en)	2016-03-16	2017-09-21	Halozyme, Inc.	Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017158436A1 (en)	2016-03-17	2017-09-21	Oslo Universitetssykehus Hf	Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017165464A1 (en)	2016-03-21	2017-09-28	Elstar Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
US10745487B2 (en)	2016-03-22	2020-08-18	Bionomics Limited	Method of treating cancer by administering an anti-LGR5 monoclonal antibody
CA3018365A1 (en)	2016-03-23	2017-09-28	The General Hospital Corporation	Assays and methods for detecting udp-glucose
EP3433274A1 (en)	2016-03-25	2019-01-30	Visterra, Inc.	Formulation of antibody molecules to dengue virus
CA3019164A1 (en)	2016-03-29	2017-10-05	Janssen Biotech, Inc.	Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en)	2016-04-07	2017-10-12	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP7197078B2 (ja)	2016-04-08	2022-12-27	ジィールバイオ，インコーポレーテッド	プレクチン１結合性抗体およびその使用
US20170298119A1 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
CN109415441B (zh)	2016-05-24	2023-04-07	英斯梅德股份有限公司	抗体及其制备方法
CA3024508A1 (en)	2016-05-27	2017-11-30	Agenus Inc.	Anti-tim-3 antibodies and methods of use thereof
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
CA3028002A1 (en)	2016-06-27	2018-01-04	Juno Therapeutics, Inc.	Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr)	2016-06-27	2019-05-01	Juno Therapeutics Inc	Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3029977A1 (en)	2016-07-06	2018-01-11	Celgene Corporation	Antibodies with low immunogenicity and uses thereof
CA3030099A1 (en)	2016-07-08	2018-01-11	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
WO2018013714A1 (en)	2016-07-13	2018-01-18	Biogen Ma Inc.	Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
CN110461315B (zh)	2016-07-15	2025-05-02	诺华股份有限公司	使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
US20200148750A1 (en)	2016-07-21	2020-05-14	Emory University	Ebola Virus Antibodies and Binding Agents Derived Therefrom
EP3487880A1 (en)	2016-07-25	2019-05-29	Biogen MA Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
CN109803680B (zh)	2016-08-01	2024-05-17	佐马美国有限公司	甲状旁腺激素受体1(pth1r)抗体和其用途
BR112019001989A2 (pt)	2016-08-02	2019-08-20	Visterra, Inc.	polipeptídeos projetados e usos dos mesmos
WO2018027042A1 (en)	2016-08-03	2018-02-08	Bio-Techne Corporation	Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
KR20250103795A (ko)	2016-08-03	2025-07-07	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	아데노신 핵염기 편집제 및 그의 용도
EP3497214B1 (en)	2016-08-09	2023-06-28	President and Fellows of Harvard College	Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en)	2016-08-24	2018-03-01	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
US10704082B2 (en)	2016-09-15	2020-07-07	ArcherDX, Inc.	Methods of nucleic acid sample preparation
EP3512965B1 (en)	2016-09-15	2024-03-13	ArcherDX, LLC	Methods of nucleic acid sample preparation for analysis of cell-free dna
US11673971B2 (en)	2016-09-23	2023-06-13	Marengo Therapeutics, Inc.	Multispecific antibody molecules comprising lambda and kappa light chains
AU2017335771A1 (en)	2016-09-28	2019-02-28	Musc Foundation For Research Development	Antibodies that bind interleukin-2 and uses thereof
GB201616596D0 (en)	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies
SMT202500497T1 (it)	2016-09-30	2026-01-12	Janssen Biotech Inc	Metodo sicuro ed efficace di trattamento della psoriasi con anticorpo specifico anti-il23
JP2019535015A (ja)	2016-10-03	2019-12-05	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
MY200337A (en)	2016-10-07	2023-12-20	Novartis Ag	Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
TWI773694B (zh)	2016-10-11	2022-08-11	美商艾吉納斯公司	抗ｌａｇ－３抗體及其使用方法
AU2017342543B2 (en)	2016-10-14	2024-06-27	President And Fellows Of Harvard College	AAV delivery of nucleobase editors
WO2018071576A1 (en)	2016-10-14	2018-04-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Treatment of tumors by inhibition of cd300f
JP2020500214A (ja)	2016-11-02	2020-01-09	イミュノジェン・インコーポレーテッド	抗体薬物複合体とｐａｒｐ阻害剤との併用治療
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
AU2017353939B2 (en)	2016-11-07	2025-01-30	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
DE102016121899A1 (de) *	2016-11-15	2018-05-17	Immatics Biotechnologies Gmbh	Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
KR20190078648A (ko)	2016-11-16	2019-07-04	얀센 바이오테크 인코포레이티드	항-il23 특이적 항체로 건선을 치료하는 방법
EP3541847A4 (en)	2016-11-17	2020-07-08	Seattle Genetics, Inc.	COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
MA50948A (fr)	2016-12-07	2020-10-14	Agenus Inc	Anticorps et procédés d'utilisation de ceux-ci
AU2017373944B2 (en)	2016-12-07	2022-02-03	Agenus Inc.	Anti-CTLA-4 antibodies and methods of use thereof
EP3554561B1 (en)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Cd137 binding fibronectin type iii domains
EP3554535A4 (en)	2016-12-14	2020-10-21	Janssen Biotech, Inc.	PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
BR112019012154A2 (pt)	2016-12-14	2019-11-12	Janssen Biotech, Inc.	domínios do tipo iii da fibronectina de ligação a cd8a
GB201621635D0 (en)	2016-12-19	2017-02-01	Ucb Biopharma Sprl	Crystal structure
US11820979B2 (en)	2016-12-23	2023-11-21	Visterra, Inc.	Binding polypeptides and methods of making the same
US10745677B2 (en)	2016-12-23	2020-08-18	President And Fellows Of Harvard College	Editing of CCR5 receptor gene to protect against HIV infection
CA3088855A1 (en)	2017-01-06	2018-07-12	Scholar Rock, Inc.	Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018129395A1 (en)	2017-01-06	2018-07-12	Scholar Rock, Inc.	Methods for treating metabolic diseases by inhibiting myostatin activation
CN110382530A (zh)	2017-01-06	2019-10-25	供石公司	亚型特异性、背景许可性TGFβ1抑制剂及其用途
US11382983B2 (en)	2017-01-13	2022-07-12	Academia Sinica	Reloadable hydrogel system for treating brain conditions
WO2018130660A1 (en)	2017-01-13	2018-07-19	Academia Sinica	Reloadable hydrogel system for treating myocardial infarction
KR102697723B1 (ko)	2017-01-18	2024-08-21	비스테라, 인크.	항체 분자-약물 접합체 및 이의 용도
CN110234351A (zh)	2017-01-30	2019-09-13	詹森生物科技公司	用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
US10240205B2 (en)	2017-02-03	2019-03-26	Population Bio, Inc.	Methods for assessing risk of developing a viral disease using a genetic test
MX2019009359A (es)	2017-02-06	2020-01-30	Australian Meat & Live Stock	Composiciones inmunoestimulantes y usos de las mismas.
CA3052578A1 (en)	2017-02-07	2018-08-16	Janssen Biotech, Inc.	Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US20200291089A1 (en)	2017-02-16	2020-09-17	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
US11685776B2 (en)	2017-03-02	2023-06-27	Novartis Ag	Engineered heterodimeric proteins
MX2019010202A (es)	2017-03-03	2019-10-02	Seattle Genetics Inc	Compuestos que interactuan con glicano y metodos de uso.
US12390514B2 (en)	2017-03-09	2025-08-19	President And Fellows Of Harvard College	Cancer vaccine
EP3592853A1 (en)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Suppression of pain by gene editing
US11542496B2 (en)	2017-03-10	2023-01-03	President And Fellows Of Harvard College	Cytosine to guanine base editor
CA3261113A1 (en)	2017-03-23	2025-10-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
BR112019019655A2 (pt)	2017-03-23	2020-04-22	Harvard College	editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018176019A1 (en)	2017-03-24	2018-09-27	The Regents Of The University Of California	Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
WO2018187227A1 (en)	2017-04-03	2018-10-11	Concologie, Inc.	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2018189611A1 (en)	2017-04-12	2018-10-18	Pfizer Inc.	Antibodies having conditional affinity and methods of use thereof
JP7297672B2 (ja)	2017-04-13	2023-06-26	アジェナスインコーポレイテッド	抗ｃｄ１３７抗体およびその使用方法
WO2018191531A1 (en)	2017-04-15	2018-10-18	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
CA3058944A1 (en)	2017-04-19	2018-10-25	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
JP2020517242A (ja)	2017-04-21	2020-06-18	スターテン・バイオテクノロジー・ベー・フェー	抗ＡｐｏＣ３抗体およびその使用方法
CA3059769A1 (en)	2017-04-28	2018-11-01	Elstar Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
EP3635407B1 (en)	2017-04-28	2025-09-10	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2018204363A1 (en)	2017-05-01	2018-11-08	Agenus Inc.	Anti-tigit antibodies and methods of use thereof
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
WO2018209320A1 (en)	2017-05-12	2018-11-15	President And Fellows Of Harvard College	Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3630830A1 (en)	2017-05-23	2020-04-08	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Novel cd73 antibody, preparation and uses thereof
JP7416625B2 (ja)	2017-05-25	2024-01-17	アボット・ラボラトリーズ	早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
EP3631466A1 (en)	2017-05-30	2020-04-08	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
US20210246227A1 (en)	2017-05-31	2021-08-12	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3630835A1 (en)	2017-05-31	2020-04-08	STCube & Co., Inc.	Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR102861670B1 (ko)	2017-05-31	2025-09-18	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
JP2020522562A (ja)	2017-06-06	2020-07-30	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11572541B2 (en)	2017-06-09	2023-02-07	Providence Health & Services—Oregon	Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
CN110944666B (zh)	2017-06-26	2024-12-31	博奥泰克尼公司	杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法
CN111315774B (zh)	2017-06-27	2023-12-22	纽洛可科学有限公司	抗fam19a5抗体及其用途
KR20200022447A (ko)	2017-06-27	2020-03-03	노파르티스 아게	항-tim-3 항체의 투여 요법 및 그의 용도
JP7454945B2 (ja)	2017-07-03	2024-03-25	アボット・ラボラトリーズ	血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
WO2019010164A1 (en)	2017-07-06	2019-01-10	President And Fellows Of Harvard College	Evolution of trna synthetases
CA3069438A1 (en)	2017-07-11	2019-01-17	Compass Therapeutics Llc	Agonist antibodies that bind human cd137 and uses thereof
EA202090286A1 (ru)	2017-07-14	2020-05-12	Пфайзер, Инк.	АНТИТЕЛА К MAdCAM
EP3431496A1 (en)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti- isoasp7 amyloid beta antibodies and uses thereof
KR20200031659A (ko)	2017-07-20	2020-03-24	노파르티스 아게	항-lag-3 항체의 투여 요법 및 그의 용도
US11732274B2 (en)	2017-07-28	2023-08-22	President And Fellows Of Harvard College	Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3658583A1 (en)	2017-07-28	2020-06-03	Scholar Rock, Inc.	Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019036605A2 (en)	2017-08-17	2019-02-21	Massachusetts Institute Of Technology	MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
JP2020534025A (ja)	2017-08-25	2020-11-26	プレジデントアンドフェローズオブハーバードカレッジ	ＢｏＮＴペプチダーゼの進化
MA49950A (fr)	2017-08-25	2020-07-01	Five Prime Therapeutics Inc	Anticorps anti-b7-h4 et leurs procédés d'utilisation
US11319532B2 (en)	2017-08-30	2022-05-03	President And Fellows Of Harvard College	High efficiency base editors comprising Gam
US11624130B2 (en)	2017-09-18	2023-04-11	President And Fellows Of Harvard College	Continuous evolution for stabilized proteins
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3461841B1 (en)	2017-10-02	2019-09-11	Certest Biotec, S.L.	Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
AU2018345637A1 (en)	2017-10-02	2020-03-05	Visterra, Inc.	Antibody molecules to CD138 and uses thereof
KR20210027230A (ko)	2017-10-04	2021-03-10	옵코 파마슈티칼스, 엘엘씨	암의 개인 맞춤형 치료에 관한 물품 및 방법
US11707522B2 (en)	2017-10-13	2023-07-25	Boehringer Ingelheim International Gmbh	Human antibodies to Tn antigen
AU2018352592C1 (en)	2017-10-16	2025-09-25	Beam Therapeutics, Inc.	Uses of adenosine base editors
MX2020004074A (es)	2017-10-19	2020-10-16	Debiopharm Int Sa	Producto de combinacion para el tratamiento de cancer.
WO2019077165A1 (en)	2017-10-20	2019-04-25	Institut Curie	DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
PT3625263T (pt)	2017-10-27	2025-06-20	Pure Tech Lyt Inc	Anticorpos anti-galectina-9 e as suas utilizações
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
AU2018361957B2 (en)	2017-10-31	2023-05-25	Staten Biotechnology B.V.	Anti-ApoC3 antibodies and methods of use thereof
TW201922294A (zh)	2017-10-31	2019-06-16	美商伊繆諾金公司	抗體-藥物結合物與阿糖胞苷之組合治療
KR20200076731A (ko)	2017-11-06	2020-06-29	얀센 바이오테크 인코포레이티드	항-il23 특이적 항체로 건선성 관절염을 치료하는 안전하고 유효한 방법
AU2018364630A1 (en)	2017-11-09	2020-05-21	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
CA3081602A1 (en)	2017-11-16	2019-05-23	Novartis Ag	Combination therapies
US11851497B2 (en)	2017-11-20	2023-12-26	Compass Therapeutics Llc	CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3717069A1 (en)	2017-11-27	2020-10-07	Purdue Pharma L.P.	Humanized antibodies targeting human tissue factor
WO2019113464A1 (en)	2017-12-08	2019-06-13	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
WO2019113525A2 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
CA3067055A1 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
US12406749B2 (en)	2017-12-15	2025-09-02	The Broad Institute, Inc.	Systems and methods for predicting repair outcomes in genetic engineering
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746477A1 (en)	2018-02-02	2020-12-09	Bio-Techne Corporation	Compounds that modulate the interaction of vista and vsig3 and methods of making and using
WO2019150309A1 (en)	2018-02-02	2019-08-08	Hammack Scott	Modulators of gpr68 and uses thereof for treating and preventing diseases
GB201802486D0 (en)	2018-02-15	2018-04-04	Ucb Biopharma Sprl	Methods
SG11202007821WA (en)	2018-02-21	2020-09-29	Five Prime Therapeutics Inc	B7-h4 antibody formulations
US20210032334A1 (en)	2018-02-28	2021-02-04	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
JP2021516051A (ja)	2018-03-02	2021-07-01	ファイブプライムセラピューティクス，インコーポレイテッド	Ｂ７−ｈ４抗体及びその使用方法
EP3762015B1 (en)	2018-03-05	2025-12-24	Janssen Biotech, Inc.	Guselkumab for use in the treatment of crohn's disease with a dosage regimen
KR20200130696A (ko)	2018-03-12	2020-11-19	조에티스 서비시즈 엘엘씨	항-ngf 항체 및 이의 방법
WO2019178364A2 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
AU2019235842B2 (en)	2018-03-14	2022-02-03	Surface Oncology, Inc.	Antibodies that bind CD39 and uses thereof
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178218A1 (en)	2018-03-14	2019-09-19	Memorial Sloan Kettering Cancer Center	Anti-polysialic acid antibodies and uses thereof
EP3768317A4 (en)	2018-03-22	2021-12-22	Surface Oncology, Inc.	ANTI-IL-27 ANTIBODIES AND USES THEREOF
WO2019180272A1 (en)	2018-03-23	2019-09-26	Fundación Instituto De Investigación Sanitaria De Santiago De Compostela	Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
CA3091733A1 (en)	2018-03-26	2019-10-03	Glycanostics S.R.O.	Means and methods for glycoprofiling of a protein
AR117566A1 (es)	2018-04-02	2021-08-18	Bristol Myers Squibb Co	Anticuerpos anti-trem-1 y sus usos
RU2020136055A (ru)	2018-04-06	2022-05-06	Дана-Фарбер Кэнсер Инститьют, Инк.	Kir3dl3 в качестве рецептора hhla2, анти-hhla2-антител и его использование
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019207159A1 (en)	2018-04-27	2019-10-31	Fondazione Ebri Rita Levi-Montalcini	Antibody directed against a tau-derived neurotoxic peptide and uses thereof
CN112119091B (zh)	2018-05-10	2025-01-03	纽洛可科学有限公司	抗序列相似家族19成员a5的抗体及其使用方法
WO2019222130A1 (en)	2018-05-15	2019-11-21	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and flt3 inhibitors
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
JP2021525243A (ja)	2018-05-21	2021-09-24	コンパスセラピューティクスリミテッドライアビリティカンパニー	Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
US12157760B2 (en)	2018-05-23	2024-12-03	The Broad Institute, Inc.	Base editors and uses thereof
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US11913044B2 (en)	2018-06-14	2024-02-27	President And Fellows Of Harvard College	Evolution of cytidine deaminases
US12162934B2 (en)	2018-06-18	2024-12-10	UCB Biopharma SRL	Gremlin-1 antagonist for the prevention and treatment of cancer
PE20210418A1 (es)	2018-06-19	2021-03-08	Atarga Llc	Moleculas de anticuerpo de componente de complemento 5 y sus usos
WO2019244107A1 (en)	2018-06-21	2019-12-26	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
WO2020003172A1 (en)	2018-06-26	2020-01-02	Mor Research Applications	Transthyretin antibodies and uses thereof
CN112955465A (zh)	2018-07-03	2021-06-11	马伦戈治疗公司	抗tcr抗体分子及其用途
WO2020008083A1 (es)	2018-07-05	2020-01-09	Consejo Superior De Investigaciones Científicas	Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
US12522807B2 (en)	2018-07-09	2026-01-13	The Broad Institute, Inc.	RNA programmable epigenetic RNA modifiers and uses thereof
HUE056501T2 (hu)	2018-07-11	2022-02-28	Scholar Rock Inc	Izoforma-szelektív TGF-béta1 inhibitorok és alkalmazásuk
EP3820508A1 (en)	2018-07-11	2021-05-19	Scholar Rock, Inc.	High-affinity, isoform-selective tgf?1 inhibitors and use thereof
US20210340238A1 (en)	2018-07-11	2021-11-04	Scholar Rock, Inc.	TGFß1 INHIBITORS AND USE THEREOF
US20200025776A1 (en)	2018-07-18	2020-01-23	Janssen Biotech, Inc.	Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
MA53160A (fr)	2018-07-20	2021-05-26	Pf Medicament	Récepteur pour vista
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
FI4177356T3 (fi)	2018-08-08	2024-08-07	Pml Screening Llc	Menetelmiä virustaudin kehittymisriskin arviointiin geenitestillä
EP3833442A2 (en)	2018-08-09	2021-06-16	Compass Therapeutics LLC	Antibodies that bind cd277 and uses thereof
US20210388089A1 (en)	2018-08-09	2021-12-16	Compass Therapeutics Llc	Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
US12391957B2 (en)	2018-08-17	2025-08-19	Icahn School Of Medicine At Mount Sinai	Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
CN112654711B (zh) *	2018-08-29	2024-03-26	上海科技大学	Cas蛋白抑制剂的组合物及应用
EP3850368A4 (en)	2018-09-14	2022-11-23	Prelude Corporation	PROCEDURE FOR SELECTING THE TREATMENT OF SUBJECTS AT RISK FOR INVASIVE BREAST CANCER
HRP20230886T1 (hr)	2018-09-24	2023-11-24	Janssen Biotech, Inc.	Siguran i učinkovit postupak za liječenje ulcerativnog kolitisa s protutijelom anti-il12/il23
EP3856350A1 (en)	2018-09-27	2021-08-04	Marengo Therapeutics, Inc.	Csf1r/ccr2 multispecific antibodies
CA3114295A1 (en)	2018-09-28	2020-04-02	Kyowa Kirin Co., Ltd.	Il-36 antibodies and uses thereof
WO2020070678A2 (en)	2018-10-03	2020-04-09	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
JP7555334B2 (ja)	2018-10-05	2024-09-24	バヴァリアン・ノルディック・アクティーゼルスカブ	組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
WO2020086736A1 (en)	2018-10-23	2020-04-30	Scholar Rock, Inc.	Rgmc-selective inhibitors and use thereof
GB201817311D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB201817309D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
WO2020086408A1 (en)	2018-10-26	2020-04-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A high-yield perfusion-based transient gene expression bioprocess
WO2020092453A1 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Nucleobase editors comprising geocas9 and uses thereof
BR112021008795A2 (pt)	2018-11-13	2021-08-31	Compass Therapeutics Llc	Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos
EP3883611A4 (en)	2018-11-19	2023-02-22	Dana-Farber Cancer Institute, Inc.	USE OF BIOMARKERS OF THE IRE1ALPHA-XBP1 SIGNALING PATHWAY TO MODULATE IMMUNE RESPONSE
SG11202104918PA (en)	2018-11-20	2021-06-29	Bavarian Nordic As	Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
EP3883607A4 (en)	2018-11-20	2022-08-17	Janssen Biotech, Inc.	SAFE AND EFFICIENT METHOD OF TREATMENT OF PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY
WO2020123011A1 (en)	2018-12-13	2020-06-18	Surface Oncology, Inc.	Anti-il-27 antibodies and uses thereof
MA54562A (fr)	2018-12-18	2021-10-27	Janssen Biotech Inc	Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
EP3898687A1 (en)	2018-12-20	2021-10-27	Kyowa Kirin Co., Ltd.	Fn14 antibodies and uses thereof
EP3897647B1 (en)	2018-12-20	2023-11-01	Novartis AG	Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
CN113195542B (zh)	2018-12-26	2024-05-24	南京传奇生物科技有限公司	Cd30-结合部分、嵌合抗原受体及其用途
CN113195533B (zh)	2019-01-02	2024-04-26	纽洛可科学有限公司	抗序列相似家族19成员a5的抗体及其使用方法
JP7689074B2 (ja)	2019-01-15	2025-06-05	ヤンセンバイオテツク，インコーポレーテツド	若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
BR112021013571A2 (pt)	2019-01-16	2021-09-21	Compass Therapeutics Llc	Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
GB201900732D0 (en)	2019-01-18	2019-03-06	Ucb Biopharma Sprl	Antibodies
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
KR20210118878A (ko)	2019-01-23	2021-10-01	얀센 바이오테크 인코포레이티드	건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
WO2020154548A2 (en)	2019-01-23	2020-07-30	New York University	Antibodies specific to delta 1 chain of t cell receptor
MX2021009175A (es)	2019-01-30	2021-09-14	Scholar Rock Inc	Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
US11738050B2 (en)	2019-02-01	2023-08-29	Regents Of The University Of Minnesota	Compounds binding to fibroblast activation protein alpha
EP3693063A1 (en)	2019-02-06	2020-08-12	Diaccurate	Methods and compositions for treating cancer
EP3696191A1 (en)	2019-02-14	2020-08-19	Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC)	Car t-cells for the treatment of cd1a-positive cancer
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
CA3131014A1 (en)	2019-02-21	2020-08-27	Andreas Loew	Anti-tcr antibody molecules and uses thereof
WO2020172605A1 (en)	2019-02-21	2020-08-27	Elstar Therapeutics, Inc.	Antibody molecules that bind to nkp30 and uses thereof
CN114026122B (zh)	2019-02-21	2024-12-31	马伦戈治疗公司	结合t细胞相关癌细胞的多功能分子及其用途
CN114127113A (zh)	2019-02-21	2022-03-01	马伦戈治疗公司	与钙网蛋白结合的多功能分子及其用途
CA3130628A1 (en)	2019-02-21	2020-08-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN113874081A (zh)	2019-02-26	2021-12-31	茵思博纳公司	高-亲和力抗-mertk抗体及其用途
WO2020185763A1 (en)	2019-03-11	2020-09-17	Memorial Sloan Kettering Cancer Center	Cd22 antibodies and methods of using the same
CA3133395A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
EA202192508A1 (ru)	2019-03-14	2022-03-29	Янссен Байотек, Инк.	Способы получения композиций антитела к фно
MA55282A (fr)	2019-03-14	2022-01-19	Janssen Biotech Inc	Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
JP7635137B2 (ja)	2019-03-14	2025-02-25	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための方法
CA3134079A1 (en)	2019-03-18	2020-09-24	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
CN114127285B (zh)	2019-03-19	2024-09-10	布罗德研究所股份有限公司	编辑核苷酸序列的方法和组合物
EP3947442A2 (en)	2019-03-28	2022-02-09	Danisco US Inc.	Engineered antibodies
EP3946593A1 (en)	2019-03-29	2022-02-09	Atarga, LLC	Anti fgf23 antibody
EP3956349A1 (en)	2019-04-17	2022-02-23	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
WO2020223121A1 (en)	2019-04-30	2020-11-05	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
JP7805788B2 (ja)	2019-05-23	2026-01-26	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2022536279A (ja)	2019-06-03	2022-08-15	ヤンセンバイオテツク，インコーポレーテツド	乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
CN114173873A (zh)	2019-06-03	2022-03-11	詹森生物科技公司	用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
MX2021014953A (es)	2019-06-04	2022-01-24	Janssen Biotech Inc	Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
WO2020257289A2 (en)	2019-06-17	2020-12-24	Visterra, Inc.	Humanized antibody molecules to cd138 and uses thereof
EP4004025A1 (en)	2019-07-26	2022-06-01	Visterra, Inc.	Interleukin-2 agents and uses thereof
SI4007777T1 (sl)	2019-08-02	2024-03-29	Fundacio De Recerca Clinic Barcelona-Institut D'investigacions Biomediques August Pi I Sunyer (Frcb-Idibaps)	Cart-t celice proti bcma za zdravljenje multiplega mieloma
EP4031658A1 (en)	2019-08-07	2022-07-27	DB Biotech, AS	Improved horseradish peroxidase polypeptides
US20220242962A1 (en)	2019-08-12	2022-08-04	Aptevo Research And Development Llc	4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
MX2022002315A (es)	2019-08-30	2022-03-25	Agenus Inc	Anticuerpos anti-cd96 y sus metodos de uso.
JP2022546768A (ja)	2019-09-04	2022-11-08	ワイ－バイオロジクス・インコーポレイテッド	抗ｖｓｉｇ４抗体または抗原結合フラグメントおよびその使用
WO2021044009A1 (en)	2019-09-04	2021-03-11	Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne)	Herv inhibitors for use in treating tauopathies
US11655303B2 (en)	2019-09-16	2023-05-23	Surface Oncology, Inc.	Anti-CD39 antibody compositions and methods
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
TW202521984A (zh)	2019-09-25	2025-06-01	美商表面腫瘤學有限責任公司	抗ｉｌ－２７抗體及其用途
JP2022549504A (ja)	2019-09-26	2022-11-25	エスティーキューブアンドカンパニー	グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
CN114829404B (zh)	2019-10-09	2025-09-09	斯特库比公司	对糖基化的lag3特异的抗体及其使用方法
US12435330B2 (en)	2019-10-10	2025-10-07	The Broad Institute, Inc.	Methods and compositions for prime editing RNA
EP4045061A4 (en)	2019-10-14	2024-04-17	ARO Biotherapeutics Company	CD71-BINDING FIBRONECTIN TYPE III DOMAINS
US11781138B2 (en)	2019-10-14	2023-10-10	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en)	2019-10-14	2025-12-09	Aro Biotherapeutics Company	EPCAM binding fibronectin type III domains
BR112022007179A2 (pt)	2019-10-21	2022-08-23	Novartis Ag	Inibidores de tim-3 e usos dos mesmos
IL292347A (en)	2019-10-21	2022-06-01	Novartis Ag	Combination treatments with ventoclax and tim-3 inhibitors
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
MX2022005664A (es)	2019-11-20	2022-09-07	Bavarian Nordic As	Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer.
GB201917480D0 (en)	2019-11-29	2020-01-15	Univ Oxford Innovation Ltd	Antibodies
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
IL293889A (en)	2019-12-20	2022-08-01	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4084821A4 (en)	2020-01-03	2024-04-24	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
EP4084823A4 (en)	2020-01-03	2024-05-15	Marengo Therapeutics, Inc.	ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
WO2021142002A1 (en)	2020-01-06	2021-07-15	Vaccinex, Inc.	Anti-ccr8 antibodies and uses thereof
EP4087659A2 (en)	2020-01-11	2022-11-16	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
TW202135862A (zh)	2020-01-11	2021-10-01	美商供石公司	TGFβ抑制劑及其用途
TWI869528B (zh)	2020-01-13	2025-01-11	美商威特拉公司	C5ar1抗體分子及其用途
WO2021144657A1 (en)	2020-01-17	2021-07-22	Novartis Ag	Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021150925A1 (en)	2020-01-24	2021-07-29	Dana-Farber Cancer Institute, Inc.	Uses of biomarkers for improving immunotherapy
CN115397848A (zh)	2020-02-05	2022-11-25	拉利玛生物医药公司	Tat肽结合蛋白及其用途
US20230151108A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd137
EP4103612A1 (en)	2020-02-13	2022-12-21	UCB Biopharma SRL	Bispecific antibodies against cd9
US20230125234A1 (en)	2020-02-13	2023-04-27	UCB Biopharma SRL	Anti cd44-ctla4 bispecific antibodies
WO2021160267A1 (en)	2020-02-13	2021-08-19	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd7
US20230192900A1 (en)	2020-02-13	2023-06-22	UCB Biopharma SRL	Bispecific antibodies binding hvem and cd9
US20230220074A1 (en)	2020-02-18	2023-07-13	Alector Llc	Pilra antibodies and methods of use thereof
CN115768465A (zh)	2020-03-06	2023-03-07	Ona疗法有限公司	抗cd36抗体及其治疗癌症的用途
WO2021183207A1 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
MX2022011289A (es)	2020-03-11	2022-12-08	Fundacio Inst De Recerca Contra La Leucemia Josep Carreras	Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).
JP2023518849A (ja)	2020-03-26	2023-05-08	バンダービルト・ユニバーシティ	重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体
WO2021202473A2 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Engineered antibodies
CA3178465A1 (en)	2020-04-03	2021-10-07	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
WO2021211331A1 (en)	2020-04-13	2021-10-21	Abbott Point Of Care Inc.	METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
KR20230028242A (ko)	2020-04-24	2023-02-28	마렝고 테라퓨틱스, 인크.	T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
EP4143236A1 (en)	2020-05-01	2023-03-08	Novartis AG	Engineered immunoglobulins
EP4143224A1 (en)	2020-05-01	2023-03-08	Novartis AG	Immunoglobulin variants
US20210347880A1 (en)	2020-05-05	2021-11-11	Janssen Biotech, Inc.	Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
DE112021002672T5 (de)	2020-05-08	2023-04-13	President And Fellows Of Harvard College	Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CA3182150A1 (en)	2020-05-17	2021-11-25	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of selecting and using the same
MX2022014430A (es)	2020-05-21	2023-02-22	Janssen Biotech Inc	Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
WO2021239666A1 (en)	2020-05-26	2021-12-02	Diaccurate	Therapeutic methods
US20230235080A1 (en)	2020-06-03	2023-07-27	Bionecure Therapeutics, Inc.	Trophoblast cell-surface antigen-2 (trop-2) antibodies
WO2021262999A1 (en)	2020-06-24	2021-12-30	Visterra, Inc.	Antibody molecules to april and uses thereof
CN116390772A (zh)	2020-07-07	2023-07-04	博泰康医药公司	新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
US20220025035A1 (en)	2020-07-13	2022-01-27	Janssen Biotech, Inc.	Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
BR112023000603A2 (pt)	2020-07-20	2023-01-31	Astrazeneca Uk Ltd	Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
EP4188443A4 (en)	2020-07-30	2024-09-18	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
EP4193149A1 (en)	2020-08-04	2023-06-14	Abbott Laboratories	Improved methods and kits for detecting sars-cov-2 protein in a sample
US11725052B2 (en)	2020-08-18	2023-08-15	Cephalon Llc	Anti-PAR-2 antibodies and methods of use thereof
WO2022047046A1 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Methods of detecting trbc1 or trbc2
CN116249718A (zh)	2020-08-26	2023-06-09	马伦戈治疗公司	结合至钙网蛋白的多功能性分子及其用途
CA3190766A1 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Antibody molecules that bind to nkp30 and uses thereof
EP4204021A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
EP4204020A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
US20230416382A1 (en)	2020-10-14	2023-12-28	Five Prime Therapeutics, Inc.	Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021359092A1 (en)	2020-10-15	2023-06-01	UCB Biopharma SRL	Binding molecules that multimerise cd45
WO2022081436A1 (en)	2020-10-15	2022-04-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
AU2021365525A1 (en)	2020-10-23	2023-06-15	Hq Han	Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof
WO2022115538A1 (en)	2020-11-24	2022-06-02	Bio-Techne Corporation	Anti-severe acute respiratory syndrome coronavirus antibodies
WO2022119976A1 (en)	2020-12-01	2022-06-09	Aptevo Research And Development Llc	Heterodimeric psma and cd3-binding bispecific antibodies
WO2022119841A1 (en)	2020-12-01	2022-06-09	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
CA3203977A1 (en)	2020-12-04	2022-06-09	Visterra, Inc.	Methods of using interleukin-2 agents
AU2021401316A1 (en)	2020-12-18	2023-07-06	Kiniksa Pharmaceuticals, Gmbh	Protein compositions and methods for producing and using the same
WO2022147147A1 (en)	2020-12-30	2022-07-07	Abbott Laboratories	Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
AU2021414227A1 (en)	2020-12-31	2023-07-06	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN117425500A (zh)	2021-01-13	2024-01-19	纪念斯隆凯特琳癌症中心	抗dll3抗体-药物缀合物
CA3204628A1 (en)	2021-01-13	2022-07-21	John T. POIRIER	Antibody-pyrrolobenzodiazepine derivative conjugate
KR20230147072A (ko)	2021-01-20	2023-10-20	비스테라, 인크.	인터류킨-2 돌연변이체 및 이의 용도
US20240141060A1 (en)	2021-01-29	2024-05-02	Novartis Ag	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022182872A2 (en)	2021-02-24	2022-09-01	Alladapt Immunotherapeutics, Inc.	Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2022187440A1 (en)	2021-03-03	2022-09-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	La protien as a novel regulator of osteoclastogenesis
US20240158503A1 (en)	2021-03-03	2024-05-16	Pierre Fabre Medicament	Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2022190034A1 (en)	2021-03-12	2022-09-15	Janssen Biotech, Inc.	Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CN117751138A (zh)	2021-03-12	2024-03-22	詹森生物科技公司	用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
WO2022195551A1 (en)	2021-03-18	2022-09-22	Novartis Ag	Biomarkers for cancer and methods of use thereof
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
EP4067381A1 (en)	2021-04-01	2022-10-05	Julius-Maximilians-Universität Würzburg	Novel tnfr2 binding molecules
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en)	2021-04-08	2022-10-13	Marengo Therapeutics, Inc.	Multifuntional molecules binding to tcr and uses thereof
CA3215367A1 (en)	2021-04-14	2022-10-20	Swapnil Kulkarni	Fn3 domain-sirna conjugates and uses thereof
EP4323409A4 (en)	2021-04-14	2025-04-16	ARO Biotherapeutics Company	CD71-BINDING FIBRONECTIN TYPE III DOMAINS
US12472248B2 (en)	2021-04-29	2025-11-18	The Government Of The United States, As Represented By The Secretary Of The Army	Antibodies against fentanyl and fentanyl analogs
KR20240005809A (ko)	2021-05-07	2024-01-12	서피스 온콜로지, 엘엘씨	항-il-27 항체 및 이의 용도
CA3216320A1 (en)	2021-05-18	2022-11-24	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
EP4348263A1 (en)	2021-05-28	2024-04-10	Alexion Pharmaceuticals, Inc.	Methods for detecting cm-tma biomarkers
EP4348260A2 (en)	2021-06-03	2024-04-10	Scholar Rock, Inc.	Tgf-beta inhibitors and therapeutic use thereof
AU2022288058A1 (en)	2021-06-07	2023-11-16	Agonox, Inc.	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
US20240280561A1 (en)	2021-06-08	2024-08-22	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022266034A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
JP2024522213A (ja)	2021-06-14	2024-06-11	アルジェニクスビーブイ	抗ｉｌ－９抗体及びその使用方法
FI4358995T3 (fi)	2021-06-23	2026-02-04	Scholar Rock Inc	Mystostatiinireitin estäjä yhdessä glp-1-reitin aktivaattorin kanssa käytettäviksi metabolisten häiriöiden hoidossa
EP4362977A1 (en)	2021-06-29	2024-05-08	Seagen Inc.	Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
EP4367136A1 (en)	2021-07-09	2024-05-15	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
JP2024527581A (ja)	2021-07-09	2024-07-25	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法
AU2022308201A1 (en)	2021-07-09	2024-02-22	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
WO2023285878A1 (en)	2021-07-13	2023-01-19	Aviation-Ophthalmology	Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
EP4370541A1 (en)	2021-07-14	2024-05-22	2seventy bio, Inc.	Engineered t cell receptors fused to binding domains from antibodies
MX2024001415A (es)	2021-07-30	2024-02-27	Ona Therapeutics S L	Anticuerpos anti-cd36 y su uso para tratar el cancer.
EP4384545A1 (en)	2021-08-10	2024-06-19	BYOMass Inc.	Anti-gdf15 antibodies, compositions and uses thereof
KR20240043818A (ko)	2021-08-26	2024-04-03	글리카노스틱스 에스.알.오.	암 진단을 위한 당단백질 바이오마커
AU2022339759A1 (en)	2021-08-31	2024-03-07	Abbott Laboratories	Methods and systems of diagnosing brain injury
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
US20240391979A1 (en) *	2021-09-13	2024-11-28	Achelois Biopharma, Inc.	Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
WO2023041565A1 (en)	2021-09-14	2023-03-23	Glycanostics S.R.O	Use of lectins to determine mammaglobin-a glycoforms in breast cancer
CA3232420A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
US20250223376A1 (en)	2021-09-20	2025-07-10	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023056268A1 (en)	2021-09-30	2023-04-06	Abbott Laboratories	Methods and systems of diagnosing brain injury
CA3235627A1 (en)	2021-10-18	2023-04-27	Byomass Inc.	Anti-activin a antibodies, compositions and uses thereof
MX2024005197A (es)	2021-10-29	2024-07-24	Janssen Biotech Inc	Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23.
EP4177266A1 (en)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
WO2023084488A1 (en)	2021-11-15	2023-05-19	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
IL313021A (en)	2021-11-23	2024-07-01	Janssen Biotech Inc	Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023097254A1 (en)	2021-11-24	2023-06-01	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
EP4440594A2 (en)	2021-11-29	2024-10-09	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
EP4440598A1 (en)	2021-12-01	2024-10-09	Visterra, Inc.	Methods of using interleukin-2 agents
AU2022413677A1 (en)	2021-12-17	2024-06-27	Abbott Laboratories	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4452316A1 (en)	2021-12-22	2024-10-30	BYOMass Inc.	Targeting gdf15-gfral pathway
EP4452305A1 (en)	2021-12-23	2024-10-30	Bavarian Nordic A/S	Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023147107A1 (en)	2022-01-31	2023-08-03	Byomass Inc.	Myeloproliferative conditions
JP2025507303A (ja)	2022-02-04	2025-03-18	アボット・ラボラトリーズ	試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
WO2023150778A1 (en)	2022-02-07	2023-08-10	Visterra, Inc.	Anti-idiotype antibody molecules and uses thereof
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
WO2023187707A1 (en)	2022-03-30	2023-10-05	Janssen Biotech, Inc.	Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023192436A1 (en)	2022-03-31	2023-10-05	Alexion Pharmaceuticals, Inc.	Singleplex or multiplexed assay for complement markers in fresh biological samples
GB202205203D0 (en)	2022-04-08	2022-05-25	UCB Biopharma SRL	Combination with inhibitor
GB202205200D0 (en)	2022-04-08	2022-05-25	Ucb Biopharma Sprl	Combination with chemotherapy
EP4514381A1 (en)	2022-04-25	2025-03-05	Visterra, Inc.	Antibody molecules to april and uses thereof
JP2025514858A (ja)	2022-04-29	2025-05-09	アストラゼネカ・ユーケイ・リミテッド	ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
US20250295809A1 (en)	2022-05-13	2025-09-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
JP2025521118A (ja)	2022-05-18	2025-07-08	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ２３抗体を用いて乾癬性関節炎を評価及び治療するための方法
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
EP4296279A1 (en)	2022-06-23	2023-12-27	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-transthyretin (ttr) binding proteins and uses thereof
AU2023298134A1 (en)	2022-06-29	2024-11-28	Abbott Laboratories	Magnetic point-of-care systems and assays for determining gfap in biological samples
EP4554619A1 (en)	2022-07-15	2025-05-21	Danisco US Inc.	Methods for producing monoclonal antibodies
JP2025525530A (ja)	2022-07-15	2025-08-05	ヤンセンバイオテツク，インコーポレーテツド	抗原結合可変領域の改善された生物工学による対合のための材料及び方法
EP4565597A2 (en)	2022-08-03	2025-06-11	Voyager Therapeutics, Inc.	Compositions and methods for crossing the blood brain barrier
EP4580753A1 (en)	2022-08-31	2025-07-09	Washington University	Alphavirus antigen binding antibodies and uses thereof
CA3266222A1 (en)	2022-09-01	2024-03-07	University Of Georgia Research Foundation, Inc.	COMPOSITIONS AND METHODS OF DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH
WO2024054436A1 (en)	2022-09-06	2024-03-14	Alexion Pharmaceuticals, Inc.	Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
JP2025532597A (ja)	2022-09-15	2025-10-01	アボット・ラボラトリーズ	軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
KR20250075625A (ko)	2022-09-21	2025-05-28	엘테라 에이쥐	L1cam에 결합하는 신규 결합 분자
EP4623001A1 (en)	2022-11-22	2025-10-01	Janssen Biotech, Inc.	Method of treating ulcerative colitis with anti-il23 specific antibody
TW202430247A (zh)	2022-12-22	2024-08-01	美商供石公司	肌肉生長抑制素活化之選擇性及強效抑制劑
WO2024168061A2 (en)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Antibody molecules binding to sars-cov-2
WO2024188356A1 (en)	2023-03-16	2024-09-19	Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.	Ilt7-targeting antibodies and uses thereof
EP4680243A1 (en)	2023-03-17	2026-01-21	The United States of America, as represented by the Secretary, Department of Health and Human Services	Methods for treatment of age-related macular degeneration
AU2024240129A1 (en)	2023-03-17	2025-10-09	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226969A1 (en)	2023-04-28	2024-10-31	Abbott Point Of Care Inc.	Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
AU2024277829A1 (en)	2023-05-19	2025-12-04	Les Laboratoires Servier	Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
AU2024277678A1 (en)	2023-05-25	2025-11-27	Dispatch Biotherapeutics, Inc.	Synthetic cancer antigens as targets for treating cancers
EP4484445A1 (en)	2023-06-26	2025-01-01	Universität zu Köln	Hcmv neutralizing antibodies
TW202521155A (zh)	2023-09-27	2025-06-01	瑞士商艾爾瑟拉股份有限公司	用於治療血液惡性疾病之l1cam結合分子
WO2025072888A2 (en)	2023-09-28	2025-04-03	Novavax, Inc.	Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
US20260022185A1 (en)	2024-01-03	2026-01-22	Kiniksa Pharmaceuticals, Gmbh	Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies
TW202540204A (zh)	2024-01-26	2025-10-16	西班牙商阿爾米雷爾有限公司	雙特異性分子及使用其的治療方法
GB202401567D0 (en)	2024-02-06	2024-03-20	St Georges Hospital Medical School	Treatment of infectious disease
WO2025171388A1 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens and related methods and uses
US20250361297A1 (en)	2024-03-12	2025-11-27	Adaptam Therapeutics, S.L.	Anti- siglec-15 binding molecules and methods of use
CA3249015A1 (en)	2024-03-20	2025-10-31	Janssen Biotech, Inc.	Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025226603A1 (en)	2024-04-22	2025-10-30	Surface Oncology, LLC	Methods for treating cancer using anti-ccr8 antibodies
WO2025235419A1 (en)	2024-05-06	2025-11-13	Generate Biomedicines, Inc.	Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235420A1 (en)	2024-05-06	2025-11-13	Generate Biomedicines, Inc.	Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
EP4650368A1 (en)	2024-05-13	2025-11-19	Epok Therapeutics Inc.	Tetravalent agonists of erythropoietin receptor
WO2026006472A2 (en)	2024-06-25	2026-01-02	Kiniksa Pharmaceuticals, Gmbh	Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026003761A1 (en)	2024-06-27	2026-01-02	Janssen Biotech, Inc.	Methods of treating ulcerative colits with anti-il23 specific antibody
WO2026011013A1 (en)	2024-07-02	2026-01-08	Epibiologics, Inc.	Binding agents and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
EP0349578B2 (en) *	1987-03-02	1998-10-28	Enzon Labs Inc.	Organism carrying a Single Chain Antibody Domain at its surface.
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
WO1990005144A1 (en) *	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
CA2016841C (en) *	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
EP0404003A3 (en) *	1989-06-19	1991-10-16	Xoma Corporation	Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
CA2025398A1 (en)	1989-09-20	1992-03-15	Timothy Gerard Dinan	Diagnosis and treatment of a disorder of the gastrointestinal tract
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU8081491A (en) *	1990-06-01	1991-12-31	Cetus Corporation	Compositions and methods for identifying biologically active molecules
US5723286A (en) *	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9019812D0 (en)	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
IL99552A0 (en) *	1990-09-28	1992-08-18	Ixsys Inc	Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5871974A (en) *	1990-09-28	1999-02-16	Ixsys Inc.	Surface expression libraries of heteromeric receptors
GB9022190D0 (en) *	1990-10-12	1990-11-28	Perham Richard N	Immunogenic material
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
AU1457992A (en) *	1991-03-01	1992-10-06	Stratagene	Pcr generated dicistronic dna molecules for producing antibodies
ATE269401T1 (de) *	1991-04-10	2004-07-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
ATE210189T1 (de) *	1992-09-04	2001-12-15	Scripps Research Inst	Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren

1992
- 1992-04-10 AT AT92910558T patent/ATE269401T1/de active
- 1992-04-10 JP JP51064992A patent/JP3672306B2/ja not_active Expired - Lifetime
- 1992-04-10 ES ES04076718T patent/ES2315612T3/es not_active Expired - Lifetime
- 1992-04-10 PT PT100379A patent/PT100379B/pt not_active IP Right Cessation
- 1992-04-10 DE DE69233750T patent/DE69233750D1/de not_active Expired - Lifetime
- 1992-04-10 AU AU17856/92A patent/AU662148B2/en not_active Expired
- 1992-04-10 EP EP04076718A patent/EP1471142B1/en not_active Expired - Lifetime
- 1992-04-10 ES ES92910558T patent/ES2223040T3/es not_active Expired - Lifetime
- 1992-04-10 IE IE116992A patent/IE921169A1/en not_active IP Right Cessation
- 1992-04-10 WO PCT/US1992/003091 patent/WO1992018619A1/en not_active Ceased
- 1992-04-10 DK DK04076718T patent/DK1471142T3/da active
- 1992-04-10 AT AT04076718T patent/ATE414768T1/de active
- 1992-04-10 DK DK92910558T patent/DK0580737T3/da active
- 1992-04-10 US US08/133,011 patent/US5658727A/en not_active Expired - Lifetime
- 1992-04-10 EP EP92910558A patent/EP0580737B1/en not_active Expired - Lifetime
- 1992-04-10 CA CA 2108147 patent/CA2108147C/en not_active Expired - Lifetime
- 1992-04-10 DE DE69233367T patent/DE69233367T2/de not_active Expired - Lifetime
1993
- 1993-10-08 FI FI934422A patent/FI120309B/fi not_active IP Right Cessation
- 1993-10-08 NO NO19933610A patent/NO319371B1/no not_active IP Right Cessation
1994
- 1994-10-12 US US08/322,730 patent/US5759817A/en not_active Expired - Lifetime
1997
- 1997-08-08 US US08/907,739 patent/US6235469B1/en not_active Expired - Fee Related
2000
- 2000-12-04 US US09/729,597 patent/US6468738B1/en not_active Expired - Fee Related
2002
- 2002-08-26 JP JP2002289257A patent/JP4108430B2/ja not_active Expired - Lifetime
- 2002-10-18 US US10/273,973 patent/US7118866B2/en not_active Expired - Fee Related
2005
- 2005-02-28 JP JP2005054302A patent/JP4118896B2/ja not_active Expired - Lifetime
- 2005-12-22 US US11/315,970 patent/US7985841B2/en not_active Expired - Fee Related
2007
- 2007-05-16 JP JP2007130665A patent/JP4118938B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2003204797A (ja)	2003-07-22
JP2007222179A (ja)	2007-09-06
DE69233367D1 (de)	2004-07-22
NO933610L (no)	1993-12-10
DE69233750D1 (de)	2009-01-02
CA2108147C (en)	2009-01-06
EP1471142A1 (en)	2004-10-27
JP2005218449A (ja)	2005-08-18
EP0580737A1 (en)	1994-02-02
US20040002057A1 (en)	2004-01-01
AU662148B2 (en)	1995-08-24
JP4108430B2 (ja)	2008-06-25
JP3672306B2 (ja)	2005-07-20
WO1992018619A1 (en)	1992-10-29
US20060257856A1 (en)	2006-11-16
US7985841B2 (en)	2011-07-26
US6468738B1 (en)	2002-10-22
ES2223040T3 (es)	2005-02-16
US7118866B2 (en)	2006-10-10
US5658727A (en)	1997-08-19
PT100379B (pt)	1999-01-29
NO319371B1 (no)	2005-07-25
ES2315612T3 (es)	2009-04-01
FI120309B (fi)	2009-09-15
US6235469B1 (en)	2001-05-22
EP0580737A4 (en)	1996-04-24
DK0580737T3 (da)	2004-11-01
DE69233367T2 (de)	2005-05-25
CA2108147A1 (en)	1992-10-11
JP4118938B2 (ja)	2008-07-16
ATE269401T1 (de)	2004-07-15
US5759817A (en)	1998-06-02
FI934422A0 (fi)	1993-10-08
PT100379A (pt)	1993-08-31
AU1785692A (en)	1992-11-17
DK1471142T3 (da)	2009-03-09
NO933610D0 (no)	1993-10-08
JP4118896B2 (ja)	2008-07-16
EP1471142B1 (en)	2008-11-19
EP0580737B1 (en)	2004-06-16
JPH06506836A (ja)	1994-08-04
ATE414768T1 (de)	2008-12-15
IE921169A1 (en)	1992-10-21

Publication	Publication Date	Title
FI934422L (fi)	1993-12-08	Bibliotek av heterodimera receptorer med anvaendning av fagemider
FI933882L (fi)	1993-09-06	Styrning av cellulaer immunitet med receptorchimera
FI931406L (fi)	1993-03-29	Foerfarande foer framstaellning av lineariskt polyeten med laog taethet
FI923888L (fi)	1993-03-05	Tillslutare med automatisk tryckutjaemning
FI922193L (fi)	1992-11-18	Expansionspropp med friktionsminskande beskiktning
FI922162A7 (fi)	1992-11-15	Doerrstaengningsanordning med laosningsmekanism foer hissar
FI921840L (fi)	1992-10-26	Monoalkylfosfinat- och monoalkylfosfonatsampolymerer med laog molekylvikt
FI922226L (fi)	1992-11-18	Elektrostatisk hoegspaenningsmaolfaergssprutpistol med laogt tryck
FI920718L (fi)	1992-08-21	Vaetskefoerdelare med indraget foerdelningsmunstycke
FI914594L (fi)	1992-11-29	Kiseldioxidpoleruppslamningar med laog natrium- och metallhalt
FI933736L (fi)	1993-08-25	Behandling av cellulit med retinoider
FI921410L (fi)	1992-10-03	Lyftanordningsmaterial med rivraemsor
FI923054L (fi)	1993-01-03	Vinylmonomerkomposition med accelererad ythaerdning
FI920971L (fi)	1992-09-08	Slangformigt livsmedelshoelje med foerbaettrad avskalning
FI922144A7 (fi)	1992-11-14	Baeranordning med upprivbara bandsegment
FI920440L (fi)	1992-09-12	Squid-maetningsanordning foersedd med skyddsorgan
FI923497A7 (fi)	1993-02-10	Roterande anslutning med laonglivad taetning
FI923541L (fi)	1993-02-08	Schaberanordning med schaberbalk
FI920734L (fi)	1992-08-22	Ketosyror innehaollande kinoliner med leukotrienantagonisteffekt
FI922774L (fi)	1992-12-18	Effektfaktorkorrigerande enstegsomvandlare med en isolerad utgaong
FI933542L (fi)	1993-08-11	Blekning av lignocellulosamaterial med aktiverat syre
FI921811A7 (fi)	1992-10-24	Foerfarande foer framstaellning av maongskiktspappers- och maongskiktspapprodukter med oekad styvhet
FI931583L (fi)	1993-06-18	Foerfarande foer framstaellning av optiskt aktiva cyanhydriner med hjaelp av enzymer
FI915529L (fi)	1993-03-24	Koffeinfria kaffeprodukter med laog kaliumhalt
FI920970L (fi)	1992-09-08	Slangformigt livsmedelshoelje med foerbaettrad avskalning

Legal Events

Date	Code	Title	Description
2009-09-15	FG	Patent granted	Ref document number: 120309 Country of ref document: FI
2012-06-11	MA	Patent expired

Date

Code

Title

Description

2009-09-15

Patent granted

Ref document number: 120309

Country of ref document: FI

2012-06-11

Patent expired